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Abstract 
Background  Prescription drug misuse is a growing public health concern globally. Routinely 
collected data provides a valuable tool for quantifying prescription drug misuse. 
 
Objective   To synthesize the global literature investigating prescription drug misuse utilizing 
routinely collected, person-level prescription/dispensing data to examine reported measures, 
documented extent of misuse and associated factors.  
 
Methods   We searched MEDLINE, Embase, CINAHL, MEDLINE In Process, Scopus citations and  
Google Scholar for relevant articles published between January 1 2000-July 31 2013. We screened 
10,803 abstracts and retrieved 281 full-text manuscripts. Fifty-two peer-reviewed, English-language 
manuscripts met our inclusion criteria: an aim/method investigating prescription drug misuse and a 
measure of misuse derived exclusively from prescription/dispensing data. 
 
Results   Four proxies of prescription drug misuse were used commonly across studies: number of 
prescribers, dispensing pharmacies, early refills and volume of drugs dispensed. We identified 89 
unique measures of misuse across the 52 studies, reflecting the heterogeneity in how measures are 
constructed; single or composite; different thresholds, cohort definitions and time period of 
assessment. Consequently, it was not possible to make definitive comparisons about the extent (range 
reported: 0.01-93.5%), variations and factors associated with prescription drug misuse. 
 
Conclusion   Routine data collections are relatively consistent across jurisdictions. Despite the 
heterogeneity of the current literature, our review identifies the capacity to develop universally 
accepted metrics of misuse applied to a core set of variables in prescription/dispensing claims. Our 
timely recommendations have the potential to unify the global research field and increase the capacity 
for routine surveillance of prescription drug misuse.  
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Key points 
 Prescription drug misuse is increasing globally. This can be monitored readily using routinely 
collected data; quantifying drug access patterns at the population-level. 
 Our review identified only four common proxies for prescription drug misuse (number of 
prescribers; number of dispensing pharmacies; volume of drug(s) dispensed; and/or 
overlapping prescriptions/early refills) yet they were used to derive 89 unique definitions of 
misuse due to variations in thresholds, or use alone or in combination.  
 We recommend the development of consistent and replicable metrics to facilitate monitoring 
and comparisons of the extent of prescription drug misuse across health care settings and over 
time. 
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1 Introduction 
Research demonstrates a high degree of variability in how drugs are prescribed and used [1]. Drugs 
including sedatives, anxiolytics, analgesics and stimulants are often taken excessively to enhance 
desired effects [1]. The consequences of excessive use are a major public health concern and include 
drug tolerance [2, 3], increased risk of side effects [3-5], overdose [6], dependence [7], hospitalization 
[5] or death [2, 8, 9]. These risks are escalated with concominant prescription drug, alcohol or illicit 
drug use [10-16]. 
 
Research methodologies including medical chart [17], surveys [18], qualitative [19, 20] and 
observational studies [21] have been used to explore prescription drug misuse. In recent decades, the 
growing availability of routinely collected health information has increased opportunities to undertake 
population-based surveillance of prescription drugs. The evidence generated from routinely collected 
data can further enhance our understanding of prescription drug misuse; patient and prescriber 
behavior, outcomes of misuse and influence policy changes on these issues. 
 
There are no universally accepted definitions of prescription drug misuse [22, 23] making 
quantification challenging. Due to the limited clinical information held in routine data collections, 
prescription drug misuse is not directly measured at the population level [23] but is commonly 
inferred based on patterns of drug access and by investigating patient interactions with prescribers and 
pharmacies.   
 
In response to concerns about the management of chronic pain treated with opioid analgesics, the US 
Food and Drug Administration (FDA) has recently sought submissions related to the post-market 
surveillance of extended release and long acting opioid formulations [24]. In particular, the FDA 
requested submissions relating to defining misuse, abuse, addiction and their consequences measured 
in routine data collections [24]. Clearly, synthesizing the global literature will add significant value to 
this endeavor.  
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Our timely systematic review aims to examine the measures, extent and factors associated with 
prescription drug misuse in observational studies based on routinely collected person-level 
prescription or dispensing data. 
 
2 Methods  
2.1 Eligible studies  
We included English-language peer-reviewed manuscripts published between January 1 2000 and 
July 31 2013 satisfying the following criteria: 
 Aim or method investigated prescription drug misuse 
 Measure of prescription drug misuse derived exclusively from person-level 
prescription/dispensing data 
 Investigated misuse in adult persons (≥18 years) 
We excluded grey literature (government reports), case reports, letters, editorials, opinion pieces, 
reviews and conference abstracts.   
 
2.2 Study identification 
2.2.1 Search strategy (Electronic supplementary material resource #1) 
We searched MEDLINE, Embase, CINAHL and MEDLINE In Process. We combined keywords and 
subject headings to identify studies investigating prescription drug misuse measured in routinely 
collected prescription/dispensing data using observational approaches. Terms included misuse, 
problematic; prescription drugs; factual databases; population surveillance, cohort studies. We 
completed three further searches using: Google Scholar [25] (reviewed first 200 results per search), 
Scopus citations (for articles citing included manuscripts) and screened back references of included 
studies, review articles and selected excluded studies. 
 
Two reviewers (BB and LM) screened the abstracts and titles of articles to identify potentially 
relevant studies. These studies were assessed independently (BB and LM) for inclusion in the review 
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using a 5-item tool based on the eligibility criteria (Electronic supplementary material resource #2). A 
third reviewer (SP) arbitrated when consensus about inclusion was not reached (18% of articles). 
 
2.3 Data Extraction 
Two independent reviewers (BB and LM) completed comprehensive data extraction for articles 
meeting our eligibility criteria (Electronic supplementary material resource #3). We extracted the 
following information:  
1. Study characteristics: year of publication; publishing journal; observation period (beginning 
and end year, and duration in months); funding source; objectives; setting; generic names of 
drug(s) investigated; data source including extent of population coverage, and terminology 
related to misuse. We also calculated lag time (year of publication minus last year of study).  
2. Cohort characteristics: number of cohort(s); cohort size(s); and cohort details including study 
inclusion/exclusion criteria. Studies reported the extent of prescription drug misuse in drug 
user cohorts (persons dispensed or prescribed the drug[s] of interest) or in misuse cohorts 
(persons exhibited behavior considered to be outside the norms of prescription drug use).  
3. Measures of prescription drug misuse: the characteristic or behavior of interest (e.g. number 
of prescribers), threshold defining behavior indicative of misuse as defined by the study 
authors (e.g. ≥4 prescribers) and time period of assessment (e.g. 6 months).  
We identified each measure as: 
o Stand-alone: investigated a single characteristic or behavior (e.g. the proportion of 
persons accessing ‘≥4 prescribers’ in 6 months); or  
o Composite: in user cohorts, the measurement of two or more characteristics or 
behaviors (e.g. the proportion of persons using ‘≥4 prescribers AND ≥4 dispensing 
pharmacies’ in 6 months). In misuse cohorts (e.g. defined by persons using ‘≥4 
prescribers’ in 6 months) the measurement of at least one additional characteristic or 
behavior (e.g. the proportion of misusers accessing ‘≥4 dispensing pharmacies’ in 6 
months).  
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4. Other prescription drug misuse-related outcomes, e.g. specific drug classes and drugs 
associated with misuse. 
5. Summary statistics: percentages or other statistics (e.g. means with standard deviation or 
medians with ranges) related to all misuse measures. Where possible we calculated the extent 
of misuse in user cohorts if not reported in individual studies. 
6. Rationale for measure(s) of misuse: any reference to previously published studies; expert 
panel recommendations; empirical derivation, or any other rationale.  
7. Comprehensiveness of reporting (BB only) according to the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) Statement Checklist for Observational, 
Population-Based Cohort Studies [26, 27].  
 
2.4 Terminology 
In the global literature, a range of terms are used to encapsulate prescription drug misuse including 
abuse, dependence, diversion, misuse, problematic or non-medical use [1, 28-30]. As such, our search 
strategies included twenty-four unique misuse-related terms to capture relevant articles. For the 
purposes of this review we use the umbrella term ‘prescription drug misuse’ to capture the continuum 
of misuse, ranging from use above the norms, through to dependence, abuse and diversion. This is 
consistent with the FDA’s terminology in their recent call for submissions on post-market opioid 
surveillance [24].  
 
2.5 Analysis 
In reviewed studies there was considerable variation in study design including: study population(s), 
medicine(s) of interest, definition(s) of misuse and outcome measures. Due to this variation, it was not 
possible or appropriate to use traditional meta-analytic approaches to pool individual study results. 
Instead, we provided a descriptive analysis, detailed the key findings of individual studies and 
summarized study features in tables and figures. Our review is consistent with AMSTAR and 
PRISMA reporting criteria (Electronic supplementary material resource #4).  
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3 Results  
3.1 Studies identified  
We screened the titles/abstracts of 10,803 articles and reviewed 281 full-text manuscripts. Fifty-two 
studies met our eligibility criteria; 38 were identified from MEDLINE, Embase, CINAHL or 
MEDLINE In Process, 2 from Google Scholar, 4 from Scopus citations and 8 from back references 
(Figure 1). We include the bibliography of the 229 excluded studies (Electronic supplementary 
material resource #5).  
 
3.2 Study features (Table 1) 
The studies were set in the US (27 studies), France (17 studies), Norway (7 studies) or Canada (1 
study). All studies from Norway used dispensing data for the entire national population; the other 45 
studies used populations within a specific province, state or region. Of the 52 included studies, 32 
(61.5%) were published between 2010 and July 2013. The median study observation period was 18 
months (range: 4-132 months, IQR: 12-37.5 months) and the median lag time was 4 years (range: 2-
15 years, IQR: 3-6 years). Most studies (21) did not report a funding source. The remaining studies 
were funded primarily by research grants (15), or the pharmaceutical industry (7). Fifty-one studies 
utilized dispensing data; one study used prescription data. Forty-six unique terms were used by study 
authors to encapsulate the concept of ‘prescription drug misuse’ (Box 1). 
 
3.2.1 Prescription drugs of interest (Table 1) 
All studies specified the drug class(es) of interest, the majority focused on opioids (35 studies) and/or 
benzodiazepines (20 studies). Twenty-nine studies further detailed the specific drugs of interest; the 
most commonly investigated drugs were codeine (10 studies) and/or diazepam (9 studies). Eleven 
studies investigated a single drug, 5 of which focused on buprenorphine, for the indications of opiate 
maintenance or pain. 
 
3.2.2 Cohort characteristics 
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Thirty-nine studies investigated misuse in a drug user cohort (dispensed drug of interest); 17 in a 
misuse cohort (authors determined drug use of cohort to be above the norms); 14 included both cohort 
types; and one did not define the user group. Approximately 93 million prescription drug users were 
observed across the studies with considerable variability in cohort size (less than 100 to >25 million 
persons). Twenty-six studies used a comparison cohort differing from the other cohort most 
commonly due to the drug of interest (9 studies); nature, degree or extent of misuse (7 studies) or 
region of residence (5 studies). Two studies matched the cohorts on specific variables including 
month of index prescription, geographic area of pharmacy, prescriber specialty, age and/or number of 
prescriptions (total and for drugs with abuse potential). 
 
3.3 Measures of prescription drug misuse (Table 2; Electronic supplementary material resource #8) 
Fifty studies defined a measure with a specific misuse threshold (e.g. ≥4 prescribers). Overall, four 
behaviors were the basis of the misuse measures, either alone or in combination: number of 
prescribers; number of dispensing pharmacies; volume of drug(s) dispensed; and/or overlapping 
prescriptions/early refills.  
 
Twenty-four studies used at least one stand-alone measure of misuse, 46 studies used at least one 
composite measure of misuse; and 20 studies used both types of measures. Of the 46 studies that used 
a composite measure, only five reported the proportion of the cohort exhibiting each component of a 
composite measure [31-35]. The other studies did not detail the relative contribution of each 
component to the extent of misuse. 
 
3.4 The extent of prescription drug misuse (Electronic supplementary material resource #8) 
The extent of misuse ranged from 0.01-93.5%, and was generally higher for stand-alone compared to 
composite measures (for the latter, individuals needed to exhibit at least two characteristics or 
behaviors, as opposed to one). The variability in the extent of misuse reported across the studies 
reflected the heterogeneity in methodology, more specifically: measures and thresholds of misuse, 
cohort definitions and the time period of assessment. 
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3.4.1 Measures and thresholds of misuse.  
We identified 89 unique definitions of misuse across 50 studies; only 13 measures were utilized in 
two or more studies (32 studies in total). There appeared to be an attempt to use pre-existing 
measure(s) of misuse within, but not between, research groups, however, some groups changed their 
misuse measures between studies.  
 
Sixteen studies reported the number of prescribers and dispensing pharmacies accessed routinely by 
drug users. As thresholds increased, the proportion of the population exhibiting the behavior 
decreased (Figures 2a and 2b). Importantly, the highest proportion of drug users visited 1-2 
prescribers or pharmacies when accessing their drug(s). Thirteen of these studies defined a threshold 
of misuse; 9 studies (69.2%) set the threshold of misuse as ≥3 prescribers or dispensing pharmacies. 
The thresholds defining misuse impact on the extent of the problem reported across studies.  
 
3.4.2 Cohort definition (drug user and misuse cohorts).  
Misuse was measured more frequently in drug user cohorts (87 instances) than misuse cohorts (33 
instances). The extent of misuse was most commonly <10% for drug users (58 instances; 66.7%) and 
>20% in misuse cohorts (23 instances; 69.7%). However, the extent of misuse ranged considerably 
between drug user (0.01-63.2%) and misuse cohorts (0.2-93.5%), reflecting the variation in the 
measures and thresholds utilized, and the cohort definition. A strict cohort definition increased the 
reported extent of misuse; misuse cohorts had stricter cohort definitions than drug user cohorts. In 
general, for drug user cohorts, a high reported extent of misuse reflected a low threshold for misuse 
and for misuse cohorts, the higher the reported extent of misuse, the stricter the cohort definition. 
 
3.4.3 Time period of assessment.  
Measures of misuse were assessed from 7 days to 4 years. The most commonly investigated time 
period was 12 months, utilized in 44% of instances of reporting misuse. Due to the heterogeneity of 
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thresholds of misuse and cohort definitions, we were unable to make any further observations 
concerning the time period of assessment. 
 
3.5 Factors associated with prescription drug misuse (Electronic supplementary material resource 
#9) 
Fifteen studies investigated variations in the extent of misuse based on drug class (four studies), 
specific drug(s) (12 studies) and/or formulation(s) of interest (three studies). 
 
Four studies compared the extent of misuse across different drug classes based on the same measure 
of misuse within each study and found opioid misuse was higher than benzodiazepine misuse (no 
statistical comparisons were performed) [36-39].  
 
Six studies compared the extent of misuse for two or more drugs in the same class. In the opioid class, 
oxycodone (compared to tapentadol) and methadone (compared to morphine, oxycodone, fentanyl, 
hydrocodone) had a significantly higher risk of misuse-related behavior [40, 41]. Within the 
benzodiazepine class, three studies demonstrated that flunitrazepam had the highest extent of misuse 
compared to several other benzodiazepines [42-44]. Within the antidepressant class, tianeptine had the 
highest extent of misuse (compared to mianserin) [44]. However, no statistical comparisons were 
performed in the benzodiazepine or antidepressant studies. 
 
Three studies explored the influence of the drug formulation on the extent of misuse and found a 
larger proportion of stronger benzodiazepines [42] and short acting opioids [45] were dispensed to a 
misuse cohort compared to weaker or long acting counterparts, respectively.  
 
3.6 Justification of measures of misuse 
Thirty-four studies reported a basic rationale for at least one measure of misuse by either citing 
previously published work (24 studies) mostly their own; using recommendations of an expert panel 
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(6 studies); and/or via empirical analysis (14 studies). Ten studies utilized more than one method of 
justification. Eighteen studies did not report a rationale for their choice of measure of misuse. 
 
3.7 Comprehensiveness of reporting observational studies  
The median STROBE score was 27 (range: 19 to 33, IQR: 23-29) out of a possible 36. Many studies 
did not report basic cohort details including sex (20), age (18) and/or cohort size (8). Studies did not 
identify how they managed any bias (26), loss to follow up (39), missing data (39) or sensitivity 
analyses (38). Furthermore, 21 studies did not report the funding source. 
 
Forty studies were published from 2008, after the STROBE statement was published; the median 
STROBE score was 25.5 (range: 19 to 31, IQR: 22-30) for studies published prior to the STROBE 
statement and 27 (range: 19 to 33, IQR: 24-29) for studies published post the STROBE publication. 
 
4 Discussion 
Our systematic review synthesized the global literature quantifying prescription drug misuse based on 
population-level, routinely collected data. Our aim was to examine the measures, extent and factors 
associated with prescription drug misuse. We found a high level of consistency in the behaviors 
measuring misuse across the 52 studies, reflecting common jurisdictional data holdings and the 
limited number of variables with the capacity to investigate misuse behavior in routine data 
collections. However, due to the heterogeneity in thresholds of misuse, cohort definitions and time 
period of assessment we were unable to make definitive comparisons regarding the extent or factors 
associated with misuse across time or jurisdictions. Despite this significant limitation in the current 
literature, going forward, the international research community has the capacity to make significant 
and timely inroads in this field by developing and harmonizing minimum-reporting standards for a 
core set of pre-defined metrics. Our review and recommendations are timely and highly pertinent to 
the recent FDA call for submissions regarding the post-market surveillance of specific prescribed 
opioids [24]. 
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The harms associated with prescription drug misuse, particularly opioid misuse, have now reached 
epidemic proportions in many jurisdictions internationally [46, 47]. Despite the escalation in 
prescription drug use and consequences of misuse across jurisdictions [8, 48, 49], we have limited 
knowledge about the extent of, and variations in, population-level misuse globally. We propose that a 
comprehensive and harmonized evidence-base, underpinned by routinely collected data, monitoring 
the extent of prescription drug misuse, will add significant value to the global effort in quantifying 
this problem. Moreover, this effort will enhance our understanding of the impact of policy responses 
attempting to address this problem. 
 
***The use of dispensing claims for post-market drug surveillance is a cost-effective means of 
monitoring longitudinal, population-level prescription drug use and misuse. Many regulatory and 
funding agencies globally use dispensing claims to monitor prescription drug use, misuse and/or 
diversion [23]. In this review we demonstrate routine dispensing data is used increasingly in peer-
reviewed literature to explore prescription drug misuse, with over 60% of reviewed studies published 
since 2010. Findings from population-level routinely collected dispensing/prescription data have the 
capacity to complement other methodological approaches such as detailed medical record reviews, 
surveys and in-depth qualitative studies to enhance our understanding of prescription drug misuse. 
Moreover, linking dispensing claims with other routinely collected health data, such as 
hospitalizations and vital status will also provide further insight into the risk factors and drug access 
patterns related to harm.  
 
Our review has several limitations. It is not certain that all relevant studies were captured. We 
reviewed over 10,000 abstracts and employed a comprehensive search strategy to identify relevant 
articles [50], 14 were identified through back references, Scopus citations or Google Scholar searches, 
indicating the challenges of targeted searching and the diversity of keywords and subject headings 
used across studies and databases. We excluded articles that were not published in English; as nearly 
half of included studies originated from Europe we may have missed studies published in other 
languages [51, 52]. Our estimates of prescription drug misuse are solely from the perspective of the 
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health care payer; we are unable to address access issues outside the dispensing episodes observed in 
our data set including medication obtained illegally. We applied the STROBE guidelines to all 
studies, irrespective of publication date. However, the results did not vary considerably for studies 
published prior to or post STROBE statement publication. We did not undertake a search of journal 
contents due to the diversity of journals where the studies were published (32 different journals for 52 
studies) [52]. These limitations do not impact our key findings. In fact, adding more studies is likely 
to contribute further to the heterogeneity we found across the field. We categorized studies and 
metrics to synthesize the disparate literature. For example, we categorized misuse measures as stand-
alone or composite measures. All measures based on a single behavior (e.g. ≥4 prescribers in 6 
months) applied in a misuse cohort were categorized as composite measures as cohort members were 
identified as potential misusers. These measures could have been categorized as stand-alone 
measures. However, this choice impacts on data presentation, not key findings. Finally, a key 
limitation of the literature is the notable absence of validation to establish whether the proxies actually 
measure misuse or are associated with harm [23].  
 
Despite these limitations, this is one of the most comprehensive systematic reviews of this field to 
date. Our review was highly focused on measuring prescription drug misuse in routinely collected 
data. Other published reviews focused on jurisdiction-specific literature [23, 47, 53-56]; self-report or 
medical chart data to ascertain use [47, 55-57]; specific drug classes [23, 53, 54, 57] or patient 
populations [54-57]. The interpretation of these reviews were also impeded by the heterogeneity in 
study design [54, 56] and/or methods [47, 54-56]. However, the authors of these reviews did not 
suggest any practical solutions for unifying research in the field. Our recommendations provide a 
foundation that will increase the dialogue between researchers and unify future routine monitoring and 
post-market surveillance research (see section 4.1). Our study complements two recent comprehensive 
reviews; one examining the patient, prescriber and environmental characteristics associated with 
opioid-related death [54]; and an overview by FDA researchers of the appropriateness of US data 
sources for measuring prescribed opioid abuse [23]. 
 
15 
4.1 Reporting recommendations 
We have developed recommendations to harmonize the measurement and reporting of prescription 
drug misuse in routine data collections. These recommendations were not part of the original study 
objectives, instead they are underpinned by the learning in this review, particularly the challenges we 
faced in identifying studies and comparing the extent of misuse across studies (Box 2). Our 
recommendations center around three key areas: methodology (promotion of consistent metrics to 
determine appropriate measures of misuse); reporting (listing all drugs by generic name included in 
each study and the specifics of the misuse measures), and study nomenclature (where possible, 
consistency in the use of key words including ‘prescription drug misuse’ that facilitate direct mapping 
to searchable subject headings). Future studies should combine these recommendations with the 
current standard reporting requirements for observational studies [26, 27], which will support the 
current FDA initiative and add value across other jurisdictions.  
 
5. Conclusion 
Prescription drug misuse has reached epidemic proportions in the US and is fast increasing in other 
jurisdictions. Despite the consistency in data holdings and behaviors used to define misuse in routine 
data collections across jurisdictions, we found considerable variation in measures of prescription drug 
misuse, cohort definitions and time periods of assessment. The adoption of new or modifications to 
existing policies targeting prescription drug misuse are much easier to argue for (or against) when the 
impact is measured robustly and consistent, reproducible effects have been demonstrated across 
multiple settings. Thus having consistent metrics for prescription drug misuse across jurisdictions is a 
very simple step, but one with potentially far-reaching consequences. 
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Table 1 Characteristics of included studies (N=52 studies) 
  N % 
Study setting 
United States 27 51.9 
France 17 32.7 
Norway 7 13.5 
Canada 1 1.9 
Year of publication 
2000-2004 7 13.5 
2005-2009 13 25.0 
2010-2013 32 61.5 
Length of observation period for routinely collected data 
< 12 months 5 9.6 
12-24 months (inclusive) 28 53.8 
25 months to 48 months (inclusive) 11 21.2 
49 months to 108 months (inclusive) 7 13.5 
>108 months 1 1.9 
Lag time (year published - last year of observation) 
1-2 years 4 7.7 
3-5 years 34 65.4 
6-10 years 8 15.4 
> 10 years 6 11.5 
Study funding 
Grants: non-government, government or research 15 28.8 
Industry: pharmaceutical company 7 13.5 
Core government funding 3 5.8 
Other 4 7.7 
23 
No funding 2 3.8 
Not disclosed 21 40.4 
Number of prescription drug classes investigated per study 
One  39 75.0 
Two 5 9.6 
Three 6 11.5 
Four 2 3.8 
Drug classes investigated for misusea 
Opioids (incl. controlled substances) 35 46.1 
Benzodiazepine 20 26.3 
Z-drug (zopiclone; zolpidem) 5 6.6 
Antidepressant 4 5.3 
Other sedative (carisoprodol) 4 5.3 
Central nervous system stimulant 3 3.9 
Anorectic (diuretic) 2 2.6 
Anticholinergic antiparkinson drug 1 1.3 
Antipsychotic 1 1.3 
Psychotropic (not further specified) 1 1.3 
a Studies investigated >1 drug type; % represents prevalence of each drug class studied (/76
24 
Table 2 Summary of measures with a defined threshold of prescription drug misuse (N=50 studies) 
Measure details 
(authors defined threshold of misuse 
behaviour) 
Stand-alone  
measure 
(24 studies) 
Studies 
Behaviour used 
in composite 
measure 
(46 studies) 
Studies Totala 
Number of prescribers  
(mode: 4; range: 2-7) 
9 
[34, 41, 58-
64] 
32 
[13, 31, 34, 36-40, 42-45, 
59, 61, 62, 64-80] 
36 
Number of dispensing pharmacies 
(mode: 4; range: 2-4) 
10 
[33, 34, 58, 
61-64, 81-
83] 
25 
[31, 33, 34, 36-38, 40, 43, 
45, 61, 62, 64-67, 69, 72-
76, 79, 80, 82, 84] 
29 
Volume of drug dispensed (including 
number of dispensings, and dispensed 
DDD) 
14 
[32, 35, 59, 
61-63, 79, 
81, 82, 85-
89] 
23 
[33, 35, 43, 59-62, 64, 66, 
67, 69, 71, 73, 74, 76-79, 82, 
84-86, 88] 
28 
Overlapping prescriptions or early refills 6 
[31, 32, 36, 
62, 89, 90] 
21 
[32, 36, 39, 40, 42-44, 62, 
63, 65, 68-72, 75, 79-81, 
89, 90] 
22 
Use of specific prescribed drug (e.g. 
alprazolam) 
3 [32, 63, 81] 6 [32, 63, 66, 67, 81, 89] 6 
Duration of prescription drug use 
(e.g. >120 days use) 
2 [81, 89] 2 [33, 63] 4 
Dose escalation 
(e.g. 50% dosage increase in mean mg 
of drug in 2 months) 
2 [62, 83] 1 [62] 2 
Other 
(Latent analysis based on age, sex and 
method of payment) 
0 – 1 [91] 1 
a Number of unique studies investigating behavior as a stand-alone and/or composite measure of misuse
25 
 
 
Box 1. Terminology used in reviewed studies to describe prescription drug misuse 
We noted 46 different terms including: abuser, clinical abuser, decedent, dependence, deviant 
(behaviour), deviant consumer, doctor shopper/shopping, excess use, excessive dose, excessive use, 
excessive user, extreme population, forgery behaviour, fraudulent behaviour, heavy shopper, high 
consumer, high risk use, high usage, high user, inappropriate dispensing, inappropriate prescription, 
inappropriate use, long term user, misuse, moderate user, multiple prescriber episode, occasional user, 
overconsumption, overconsumer, overutilization, persistent use(r), pharmacy hopping, pharmacy 
shopper, potentially aberrant, potentially inappropriate use, potentially problematic use, probably 
problematic behaviour, problematic use(r), putative acceptable use, questionable activity, recurrent 
user, repeat user, shopper, shopping behaviour, transgression behaviour, or user.  
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Box 2. Recommendations for observational studies using routinely collected data to 
investigate prescription drug misuse 
We recommend researchers should state explicitly the following issues in each published 
manuscript: 
Methodology 
1. Detail the distribution of the behavior(s) and the rationale for the threshold(s) for misuse 
Reporting 
2. List the generic name of all prescription drugs studied  
3. Detail cohort characteristics for every analysis undertaken 
4. Identify all behaviors (variables) and thresholds used to measure misuse  
5. State the time period in which the behavior(s) is measured (we recommend that studies 
should report for a six month period at a minimum) 
6. When using a composite measure of misuse, report the extent of misuse for each 
component and the composite 
Study nomenclature 
7. Use ‘prescription drug misuse’ as a key word or subject heading 
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Electronic Supplementary Material #1 Detailed Search Strategies Executed in Systematic Review 
 
1. MEDLINE search strategy (N=5,136)a 
1. Prescription drug or 
substance abuse 
related term 
2. Epidemiology and 
related methods term 
3. Routinely collected 
data 
4. A prescription drug 
misuse-related 
keyword 
Central nervous 
system agentsb 
Pharmacoepidemiology Pharmacovigilance Addic* 
Benzodiazepines Epidemiology Insurance, health Abus* 
Substance related 
disorders 
Product surveillance, 
postmarketing 
Universal coverage Misus* 
Substance abuse 
detection 
Epidemiological methods National health 
programs 
Devian* 
Polypharmacy Physician’s practice 
patterns 
Health benefit plans, 
employees 
Aberran* 
Pharmaceutical 
services 
Drug utilization Insurance, health, 
reimbursement 
Depend* 
Prescription drug 
misuse 
Health services Centers for Medicare 
and Medicaid Services 
Nonmed* 
Prescription drugs Health services 
accessibility 
Medicaid Diver* 
Drug prescriptions Public health Databases, factual Seek* 
 Population surveillance Insurance coverage Inapprop* 
 Cohort studies Insurance benefits Problem* 
 Retrospective studies Single-payer system Illeg* 
 Health services misuse Reimbursement, 
incentive 
Poison* 
  Registries Selfmed* 
  Pharmacies Inject* 
  Drug and narcotic 
control 
Suicid* 
  Drug monitoring Repeat* 
  Keywords: 
Claim* or reimburs* 
Withdraw* 
   Harm* 
   Unintent* 
   Recreat* 
   Shop* 
   Hopp* 
   Overlap* 
a For this search strategy: the search terms utilised in each column were combined with ‘OR’; the terms between 
columns were combined with ‘AND’. 
b The subject heading ‘central nervous system agents’ captures the majority of drug classes associated with 
misuse. For each search strategy we list any drug class(es) (as subject heading[s]) not captured by ‘central nervous 
system agents’.  
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2. EMBASE search strategy (N=6,160) a 
1. Prescription drug or 
substance abuse 
related term 
2. Epidemiology and 
related methods term 
3. Routinely collected 
data 
4. A prescription drug 
misuse-related 
keyword 
Central nervous 
system agents 
Epidemiology Government Addic* 
Benzodiazepine Postmarketing 
surveillance  
Insurance Abus* 
Psychotropic agent Retrospective study Factual database Misus* 
Central stimulant 
agent 
Drug utilization Reimbursement Devian* 
Drug dependence Health care facility Drug control Aberran* 
Prescription Health care Register Depend* 
Polypharmacy Health service  Nonmed* 
Prescription drug Drug surveillance 
program 
 Diver* 
Pharmaceutics Public health  Seek* 
Narcotic analgesic 
agent 
Cohort analysis  Inapprop* 
   Problem* 
   Illeg* 
   Poison* 
   Selfmed* 
   Inject* 
   Suicid* 
   Repeat* 
   Withdraw* 
   Harm* 
   Unintent* 
   Recreat* 
   Shop* 
   Hopp* 
   Overlap* 
a For this search strategy: the search terms utilised in each column were combined with ‘OR’; the terms between 
columns were combined with ‘AND’. 
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3. CINAHL search strategy (N=471) a 
1. Prescription drug or 
substance abuse 
related term 
2. Epidemiology and 
related methods term 
3. Routinely collected 
data 
4. A prescription drug 
misuse-related 
keyword 
Central nervous 
system agents 
Epidemiology Insurance, 
pharmaceutical 
services 
Addic* 
Substance use 
disorders 
Epidemiological 
research 
Insurance, health 
reimbursement 
Abus* 
Substance abuse 
detection 
Disease surveillance  Insurance, health Misus* 
Polypharmacy Population surveillance Insurance benefits Devian* 
Drug dependence Product surveillance Insurance coverage Aberran* 
Prescriptions, drug Drug utilization Resource databases, 
health 
Depend* 
Drugs, prescription Health resource 
utilization 
Databases, health Nonmed* 
 Practice patterns Medicaid Diver* 
 Prescribing patterns United States Centers 
for Medicare and 
Medicaid services 
Seek* 
 Pharmacy service Medicare Inapprop* 
 Pharmacy and 
pharmacology 
Insurance, Medigap Problem* 
 Public health Pharmacovigilance Illeg* 
 Retrospective design Student health services Poison* 
 Health services misuse Reimbursement, 
incentive 
Selfmed* 
 Inappropriate 
prescribing 
Drug monitoring Inject* 
  Key words:  
Claim* or reimburse* 
Suicid* 
   Repeat* 
   Withdraw* 
   Harm* 
   Unintent* 
   Recreat* 
   Shop* 
   Hopp* 
   Overlap* 
a For this search strategy: the search terms utilised in each column were combined with ‘OR’; the terms between 
columns were combined with ‘AND’.  
 6 
 
4. MEDLINE In Process search strategy (N=896)a 
1. Prescription drug or 
substance abuse 
related term 
2. Epidemiology and 
related methods term 
3. Routinely collected 
data 
4. A prescription drug 
misuse-related 
keyword 
Benzodiazepine* Epidemiol* Monitor* Addic* 
Prescri* Pharmacoepi*  Reimburs* Abus* 
Analgesic* Cohort* Claim* Misus* 
Opioid* Retro* Benefit* Devian* 
Medication* Population* Data* Aberran* 
Stimulant*   Depend* 
Antidepressant*   Nonmed* 
Anipsychotic*   Diver* 
Polypharmacy*   Seek* 
   Inapprop* 
   Problem* 
   Illeg* 
   Poison* 
   Selfmed* 
   Inject* 
   Suicid* 
   Repeat* 
   Withdraw* 
   Harm* 
   Unintent* 
   Recreat* 
   Shop* 
   Hopp* 
   Overlap* 
a For this search strategy: the search terms utilised in each column were combined with ‘OR’; the terms between 
columns were combined with ‘AND’.  
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5. Google Scholar searches (N=600) 
“Prescription drug” + excess 
“Prescription drug” + misuse 
“Prescription drug” + abuse 
 
  
 8 
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Electronic Supplementary Material #4 A Measurement Tool to Assess Systematic Reviews (AMSTAR) Checklist and Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) checklist 
Electronic Supplementary Material 4a: A Measurement Tool to Assess Systematic Reviews (AMSTAR) Checklist 
Section/topic # Checklist item Reported on 
page # 
Comments 
INTRODUCTION    
Was an “a priori” 
design provided? 
1 The research question and inclusion criteria should be established before the conduct of the 
review. 
5-6  
METHODS    
Was there 
duplicate study 
selection and data 
extraction? 
2 There should be at least two independent data extractors and a consensus procedure for 
disagreements should be in place. 
 
6  
Was a 
comprehensive 
literature search 
performed? 
 
3 At least two electronic sources should be searched. The report must include years and 
databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must 
be stated, and where feasible, the search strategy should be provided. All searches should 
be supplemented by consulting current contents, reviews, textbooks, specialized registers, 
or experts in the particular field of study, and by reviewing the references in the studies 
found. 
 
5, ESM 1  
Was the status of 
publication (i.e., 
grey literature) 
used as an inclusion 
criterion? 
 
4 The authors should state that they searched for reports regardless of their publication type. 
The authors should state whether or not they excluded any reports (from the systematic 
review), based on their publication status, language etc. 
 
5, 13  
Were the methods 
used to combine 
the findings of 
studies 
appropriate? 
5 For the pooled results, a test should be done to ensure the studies were combinable, to 
assess their homogeneity (i.e., Chi-squared test for homogeneity, I2). If heterogeneity exists, 
a random effects model should be used and/or the clinical appropriateness of combining 
should be taken into consideration (i.e., is it sensible to combine?). 
 
X Not a meta- 
analysis: 
Qualitative 
synthesis 
RESULTS    
 16 
 
Were the 
characteristics of 
the included 
studies provided? 
6 In an aggregated form, such as a table, data from the original studies should be provided on 
the participants, interventions, and outcomes. The ranges of characteristics in all the studies 
analyzed, e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, 
or other diseases should be reported. 
 
Tables 1 and 
2 
 
Was the scientific 
quality of the 
included studies 
assessed and 
documented? 
7 ‘‘A priori’’ methods of assessment should be provided (e.g., for effectiveness studies if the 
author(s) chose to include only randomized, double-blind, placebo-controlled studies, or 
allocation concealment as inclusion criteria); for other types of studies, alternative items will 
be relevant. 
5, 11-12  
Was the scientific 
quality of the 
included studies 
used 
appropriately in 
formulating 
conclusions? 
8 The results of the methodological rigor and scientific quality should be considered in the 
analysis and the conclusions of the review, and explicitly stated in formulating 
recommendations. 
 
X Not a meta- 
analysis: 
Qualitative 
synthesis 
Was the 
likelihood of 
publication bias 
assessed? 
9 An assessment of publication bias should include a combination of graphical aids (e.g., funnel 
plot, other available tests) and/or statistical tests (e.g., Egger regression test). 
 
X Not a meta- 
analysis: 
Qualitative 
synthesis 
FUNDING    
Was the conflict 
of interest 
included? 
10 Potential sources of support should be clearly acknowledged in both the systematic review 
and the included studies. 
 
8, 16, Table 
1 
 
APPENDIX    
Was a list of 
studies (included 
and excluded) 
provided? 
11 A list of included and excluded studies should be provided. 
 
ESMs 5 and 
6  
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Section/topic  # Checklist item  Reported 
on page # 
Comments 
TITLE    
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1  
ABSTRACT    
Structured 
summary  
2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
2 No 
registration 
number 
INTRODUCTION    
Rationale  3 Describe the rationale for the review in the context of what is already known.  4-5  
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
5  
METHODS    
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
X No 
registered 
protocol  
Eligibility 
criteria  
6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
5  
Information 
sources  
7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors 
to identify additional studies) in the search and date last searched.  
5  
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that 
it could be repeated.  
ESM 1  
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, 
if applicable, included in the meta-analysis).  
5-7  
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) 
and any processes for obtaining and confirming data from investigators.  
6-7, ESMs 2 
and 3 
 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
6-7, ESM 3  
Electronic Supplementary MaterialOnline resource 4 A Measurement Tool to Assess Systematic Reviews (AMSTAR) Checklist and Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) checklist (continued) 
Electronic Supplementary MaterialOnline resource 4b: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist 
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Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
X Not a meta- 
analysis: 
Qualitative 
synthesis 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.  
X Not a meta- 
analysis: 
Qualitative 
synthesis 
RESULTS    
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons 
for exclusions at each stage, ideally with a flow diagram.  
8, Figure 1  
Study 
characteristics  
18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-
up period) and provide the citations.  
ESM 7  
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 
12).  
X Not a meta- 
analysis: 
Qualitative 
synthesis 
Results of 
individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data 
for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
ESM 7 Not a meta- 
analysis: 
Qualitative 
synthesis 
Synthesis of 
results  
21 Present the main results of the review. If meta-analyses are done, include for each, confidence 
intervals and measures of consistency.  
7-12, 
Tables 1 
 
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in any 
data synthesis.  
X Not a meta- 
analysis: 
Qualitative 
synthesis 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, difference in means).   7  
Synthesis of 
results  
14 Describe the methods of handling data and combining results of studies, if done, including measures 
of consistency (e.g., I2) for each meta-analysis.  
6-7  
 19 
 
and 2 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  X STROBE 
results 11-12 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression 
[see Item 16]).  
X Not a meta- 
analysis: 
Qualitative 
synthesis 
DISCUSSION    
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main outcome; consider 
their relevance to key groups (e.g., healthcare providers, users, and policy makers).  
12-15  
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias).  
13-14  
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for 
future research.  
15  
FUNDING    
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role 
of funders for the systematic review.  
16  
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Electronic Supplementary Material 5 Reference List of Excluded Studies (N=229) 
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First author 
Year of 
Publication 
Setting 
(Observation 
period)b 
Aim(s)c  
(Drug class[es] 
of interest) 
 
Cohort(s) detailsc 
 
Measures of prescription drug misuse 
with a defined threshold 
(time period of assessment)d 
Other findings relevant to prescription drug misuse  
(time period of assessment) 
Bachs1 
2008 
Norway 
(2006)  
Describe ‘high 
users’ 
concomitant 
drug use 
(opioid). 
A) Cohort (N=386,836): 
≥1 codeine dispensing. 
Excluded if: cancer 
patient; incomplete 
patient identifiers; or, 
use in hospitals, nursing 
homes or physician’s 
office. 
1) Moderate/high codeine user (≥120 
DDD): highest 10% of codeine users (12 
months) 
A) 10.7% (n=41,459) 
2) High drug user: dispensed ≥100 DDD of 
BZD and/or ≥15 DDD of carisoprodol (12 
months) 
A) 50.1% (n=193,804); 41.9% (n=162,084) 
dispensed high amount of BZD or 
carisoprodol; 8.2% (n=31,720) dispensed 
high amounts of BZD and carisoprodol.  
*Moderate/high codeine use 
and concurrent high use of 
BZD (≥100 DDD) or 
carisoprodol (≥15 DDD) by 
sex:  
Female: 6.9%-8.1%  
Male: 4.0%-5.7%  
*From 10 years of age, 
females had higher rates of 
codeine utilization than 
males.  
*In other codeine users 
(<120 DDD in 12 months): 
9.6% received high 
amounts of BZD (≥100 
DDD), carisoprodol (≥15 
DDD) or both. 
*8% of Norwegian 
population was dispensed a 
codeine analgesic in 2006. 
Bellanger2 
2013 
France 
(Jul-Dec 
2005) 
Identify users as 
over- or normal-
drug users and 
identify 
characteristics 
associated with 
overconsumptio
n (AD and Z-
drug).  
A) Tianeptine 
(N=7,263): ≥2 tianeptine 
dispensings.  
B) Zolpidem (N=33,584): 
≥2 zolpidem 
dispensings. 
1) Doctor shopper: ≥4 prescribers (6 
months) 
A) 0.4% (n=32) 
B) 0.9% (n=300) 
2) Pharmacy shopper: ≥4 dispensing 
pharmacies (6 months) 
A) 1.1% (n=78) 
B) 1.3% (n=438) 
3) Excessive user: excessive use threshold 
derived from Peaks Over Threshold (POT) 
model (6 months) 
Threshold value: proportion (%) of cohort 
exceeding threshold 
A) 1.1: 7.2% (n=524) 
B) 2.0: 0.9% (n=318) 
*Overconsumption risk 
factors for tianeptine and 
zolpidem: younger age, 
pharmacy shopping 
behavior, consumption of ≥1 
anxiolytic drug and R ratio >1 
(>1 dispensing per 28 days). 
*Treatment by a psychiatrist 
increased the odds of 
overconsumption for 
tianeptine by 63%; and for 
zolpidem decreased the odds 
of overconsumption by 
35.6%. 
 
*Pharmacy shopping 
increased odds of 
overconsumption by: 
168.5% for tianeptine and 
518% for zolpidem users.  
*The classification rate of 
POT model:  
Sensitivity: 
A) 83%; B) 90% 
Specificity:  
A) 81%; B) 84%  
Correctly identified:  
A) 81%; B) 85% 
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Bramness3 
2007 
Norway 
(2004) 
Explore abuse 
potential of 
carisoprodol 
(other sedative). 
 
A) Cohort (N=83,713): 
≥18 years; ≥1 
carisoprodol dispensing. 
Excluded if use in a 
hospital, nursing home 
or physician’s office; 
incomplete doctor/user 
identifiers.  
1) Carisoprodol abuser (CA): ≥2 DDD/day 
in any prescription (not further specified); 
dispensed <100 DDD of opioids, and 
dispensed <100 DDD of BZD (12 months)  
A) 1.0% (n=815)  
2) BZD abuser/anxiety patient (BA): 
dispensed: ≥100 DDD of BZD and <100 
DDD of opioids (12 months)  
A) 7.8% (n=6,546) 
3) Opioid abuser/pain patient (OA): 
dispensed ≥100 DDD of opioids (12 
months)  
A) 13.6% (n=11,382) 
4) High carisoprodol user: dispensed >15 
DDD of carisoprodol  (12 months) 
A) 32.2% (n=26,914) 
5) Doctor shopper: ≥4 prescribers (time 
period not reported) 
A) 0.5% (n=429) 
•In user groups defined above, doctor 
shopper: ≥4 prescribers (time period not 
reported) 
CA: 4.5% (n=37) 
BA: 1.1% (n=69) 
OA: 2.0% (n=228) 
*Number of prescribers (time 
period not reported) 
A) 1 prescriber: 88.8% 
(n=74,305) 
2 prescribers: 9.1% (n=7,602) 
3 prescribers: 1.6% (n=1,377) 
≥4 prescribers: 0.5% (n=429) 
*Prescribed drug by a high 
volume prescriber: highest 
1% of prescribers in medicine 
volume (12 months) 
A) 9.4% (n=7,834) 
CA: 10.8% (n=88) 
BA: 25.3% (n=1,657) 
OA: 28.3% (n=3,223) 
*OAs received 48% of total 
amount of carisoprodol 
dispensed in 2004. 
*Most carisoprodol was 
dispensed to users with 
greater than recommended 
use who were also 
dispensed large amounts of 
BZDs and opioids.  
*Use of ≥4 prescribers and 
prescription from a high 
volume prescriber were 
more prevalent for drugs 
with abuse potential, i.e. 
BZDs and opioids. 
*High prescribers 
prescribed ‘almost 20%’ of 
drugs with abuse potential, 
i.e. BZDs and opioids. 
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Bramness4 
2010 
Norway 
(2004) 
Explore whether 
total 
carisoprodol 
(other sedative) 
consumption 
relates to 
prevalence of 
excessive 
carisoprodol 
use. 
A) Cohort (N=84,319): 
≥18 years; ≥1 
carisoprodol dispensings 
from a pharmacy. 
Excluded if dispensed 
from an institution (not 
further defined). 
1) Excessive carisoprodol user: dispensed 
>15 DDD of carisoprodol; used >2 times 
MRDD (time period not specified); ≥2 
carisoprodol dispensings; dispensed <100 
DDD of BZD, and dispensed <100 DDD of 
opioids (12 months)  
A) 1.0% (n=815) 
2) Highest 1% of carisoprodol users 
(dispensed ≥480 DDD of carisoprodol) (12 
months) 
A) 1.1% (n=896) 
3) Extreme carisoprodol user: dispensed 
>1000 DDD of carisoprodol (12 months) 
A) 0.2% (n=158) 
4) Proportion of carisoprodol dispensed to 
each misuse cohort (12 months) 
Excessive user: 4.5% 
Highest 1%: 18.7% 
Extreme user: 6.1% 
*Correlation between misuse 
cohort  and total 
carisoprodol consumption 
(12 months) 
Excessive user: 0.74 
Highest 1%: 0.81 
Extreme user: 0.61 
*Correlation between misuse 
cohort and mean dose (12 
months)  
Excessive user: 0.67 
Highest 1%: 0.70 
Extreme user: 0.55 
*An increase in amount of 
carisoprodol sold resulted in 
an increase in the number of 
people identified in the 
extreme user group. 
*Proportion overlap 
between misuse cohorts (12 
months) 
Excessive user: not 
reported. 
Highest 1%: 20% were in 
extreme group; 7% were 
excessive users.  
Extreme user: 4% were 
excessive users. 
*45%-64% of variation in 
prevalence of excessive use 
was explained by the total 
sales of carisoprodol. 
Cepeda5 
2012 
US 
(2008 to 18 
months after 
index drug 
dispensing) 
Compare rates 
of overlapping 
opioid 
prescriptions 
and multiple 
dispensing 
pharmacies with 
BZD (abuse 
potential) and 
diuretic (‘no 
abuse 
potential’) users 
and propose a 
definition for 
Cohort: dispensed ≥1 
medicine of interest; 3 
months of data supplied 
pre-index prescription; 
dispensing 
pharmacy(ies) supplied 
data over entire 
observation period. 
A) Opioid 
(N=25,161,024): 
dispensed ≥1 opioid. 
B) BZD (N=8,595,179): 
dispensed ≥1 BZD. 
C) Diuretic 
1) ≥1 days of overlapping prescriptions: 
written by ≥2 prescribers (18 months) 
A) 13.1% (n=3,297,891) 
B) 9.8% (n=843,654) 
C) 13.9% (n=1,168,462) 
•In persons with ≥1 days of overlapping 
prescriptions: ≥3 prescribers (18 months) 
Opioid: 5.4% (n=176,731) 
BZD: 2.5% (n=20,928) 
Diuretic: 3.2% (n=37,164) 
•In persons with ≥1 days of overlapping 
prescriptions: ≥2 dispensing pharmacies 
(18 months) 
Opioid: 21.3% (n=700,840) 
*Median days’ drug supply 
(18 months) 
A) Opioid: 10 
B) BZD: 30 
C) Diuretic: 30 
*Overlapping prescriptions 
were more common in 
persons with history of 
exposure (H) to medicine, 
than naïve users (N). 
Opioid: 38.3% (H); 8.5% (N) 
BZD: 19.5% (H); 6.0% (N) 
Diuretics: 17.5% (H); 10.8% 
(N). 
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shopping 
behavior that 
differentiates 
between drug 
classes.  
(N=8,433,456):  
dispensed ≥1 diuretic. 
BZD: 17.7% (n=149,036) 
Diuretic: 8.3% (n=97,004) 
•In persons with ≥1 days of overlapping 
prescriptions: ≥3 dispensing pharmacies 
(18 months) 
Opioid: 1.3% (n=44,071) 
BZD: 1.0% (n=8,167) 
Diuretic: 0.2% (n=2,431) 
2) ≥4 days of overlapping prescriptions 
(18 months) 
A) 7.7% (n=1,937,130) 
B) 6.8% (n=587,241) 
C) 11.1% (n=936,922) 
3) ≥1 overlapping prescriptions and ≥3 
dispensing pharmacies (18 months) 
A) 0.2% (n=44,071) 
B) 0.1% (n=8,167) 
C) 0.03% (n=2,431) 
*Opioid cohort: persons aged 
25-64 exhibited shopping 
behavior (≥2 overlapping 
prescriptions, ≥2 prescribers 
and ≥3 dispensing 
pharmacies) more commonly 
(0.3%) than older users aged 
≥65 years (0.1%); prior opioid 
users exhibited shopping 
behavior more commonly 
(0.8%) than opioid-naïve 
users (0.1%). 
 
Cepeda6 
2012 
US 
(2008 to 18 
months after 
index drug 
dispensing) 
Report 
prevalence of 
opioid shopping, 
heavy opioid 
shopping 
behavior, and 
prescriber 
characteristics 
associated with 
shopping.  
A) Patients 
(N=217,851): ≥1 opioid 
dispensings; 3 months 
of data pre-index 
prescription; dispensing 
pharmacy(ies) supplied 
data for entire 
observation period. 
B) Prescribers 
(N=858,290): prescribers 
with ≥1 opioid shopper 
as a patient.  
1) Opioid shopper: ≥1 days overlapping 
opioid prescriptions, ≥2 prescribers and 
≥3 dispensing pharmacies (1 shopping 
episode) (18 months) 
A) The extent of drug users defined as an 
opioid shopper not reported 
*Prescribers with opioid 
shoppers as patients (18 
months)  
B) 13.2% (n=113,034); 86.8% 
of prescribers had no 
shoppers as patients. 
*Prescribers with heavy 
shoppers (≥5 shopping 
episodes) as patients (18 
months)  
B) 1.7% (n=14,699); 98.3% of 
prescribers had no heavy 
shoppers as patients. 
 
*Prescriber characteristics 
associated with opioid 
shoppers: number of 
patients prescribed an 
opioid (18-35 users [OR 
4.05], 916-1831 [OR 
620.13]); male (OR 1.06); 
aged 70-79 (OR 2.01). 
*25% of prescribers, 
prescribed opioids to ≥66 
patients, accounting for 
82% of shoppers. 
*Prescriber specialties most 
associated with opioid 
shoppers as patients: pain, 
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addiction and emergency 
medicine. 
Cepeda7 
2013 
US 
(2008 to 18 
months after 
index drug 
dispensing) 
Assess 
prevalence of 
shopping 
behavior in 
opioid users; 
how soon 
shopping 
behavior occurs 
after initial 
opioid exposure; 
number of 
events per 
shopper; 
preferred 
opioids; and 
method of 
payment. 
A) Cohort 
(N=25,161,024): ≥1 
opioid dispensings; 3 
months of data pre-
index prescription; 
dispensing 
pharmacy(ies) supplied 
data over entire 
observation period. 
1) Opioid shopper: ≥1 days overlapping 
opioid prescriptions, ≥2 prescribers and 
≥3 dispensing pharmacies (1 shopping 
episode) (18 months) 
A) 0.3% (n=75,215) of users accounted for 
205,932 shopping episodes. 
•In opioid shoppers, proportion of heavy 
shoppers: ≥6 shopping episodes (18 
months)  
Opioid shoppers: 9.5% (n=7,157) of users 
accounted for 44.2% (n=90,997) of 
shopping episodes 
 
*In opioid shoppers, number 
of dispensing pharmacies (18 
months) 
3 pharmacies: 72.7% 
(n=54,658) 
4 pharmacies: 13.9% 
(n=10,460) 
5 pharmacies: 6.8% 
(n=5,080) 
6 pharmacies: 3.2% 
(n=2,439) 
≥7 pharmacies: 3.4% 
(n=2,578) 
*In opioid shoppers, number 
of prescribers (18 months) 
2 prescribers: 48.1% 
(n=36,178) 
3 prescribers: 31.6% 
(n=23,790) 
4 prescribers: 9.3% (n=6,967) 
5 prescribers: 4.5% (n=3,357) 
≥6 prescribers: 6.6% 
(n=4,923) 
*Shoppers (44.9%) more 
frequently paid in cash than 
non-shoppers (18.5%). 
*In shoppers, the most 
utilized opioids: schedule II 
and III (32.7%); 
combination formulation 
(30.7%); and IR and ER 
(25.2%) 
*Median of 234 days to 
first shopping event 
*Mean 2.7 shopping 
episodes per shopper 
*91.7% of subjects with a 
shopping behavior were 
aged 19-64 years. 
*Prior opioid users were 
13.7 times more likely to 
exhibit shopping behavior 
(1.4% vs. 0.1%) than opioid-
naïve users. 
Cepeda8 
2013 
US 
(2009 to 12 
months after 
index drug 
dispensing) 
Compare risk of 
shopping 
behavior 
between 
tapentadol 
immediate 
release (IR) and 
oxycodone IR 
Cohort: ≥1 tapentadol 
or oxycodone 
dispensing; no opioid 
dispensed in 3 months 
pre-index prescription. 
Excluded: dispensed any 
other opioid 3 days from 
index date. 
1) Opioid shopper: ≥1 days overlapping 
opioid prescriptions, ≥2 prescribers and 
≥3 dispensing pharmacies (1 shopping 
episode) (12 months) 
A) 0.2% (n=88) 
B) 0.9% (n=967) 
2) Heavy shopper: ≥5 shopping episodes 
(12 months) 
*Oxycodone users had a 
higher risk of shopping (3.5 
times higher) and heavy 
shopping behavior (OR 6.9) 
than tapentadol users. 
*Mean (SD) shopping 
episodes per person (12 
months) 
*Shopping events 
exclusively for opioid of 
interest (12 months) 
Tapentadol: 0.6% 
Oxycodone: 28% 
-Mean (SD) days to 
shopping event (12 months) 
Tapentadol: 180.0 (104.6) 
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(opioid). 
 
 
A) Tapentadol IR 
(N=42,940) 
B) Oxycodone IR 
(N=112,821)  
Cohorts were matched 
1:4 ratio on month of 
initial exposure, age, 
geographic area of 
pharmacy, prescriber 
specialty. 
A) 0.01% (n=4) 
B) 0.07% (n=80) 
•In opioid shoppers, proportion of heavy 
shoppers (12 months) 
Tapentadol: 4.5% (n=4) 
Oxycodone: 8.3% (n=80) 
 
A) 0.004 (0.1) 
B) 0.02 (0.3) 
*In opioid shoppers, mean 
(SD) shopping episodes per 
shopper (12 months) 
Tapentadol: 1.8 (1.9) 
Oxycodone: 2.1 (2.6) 
 
  
Oxycodone: 156.1 (100.9) 
Cepeda9 
2013 
US 
(2008 to 18 
months after 
index drug 
dispensing) 
Compare 
distance 
travelled to fill 
opioid 
prescriptions for 
shoppers and 
non-shoppers. 
 
A) Cohort 
(N=10,910,451): ≥3 
opioid dispensings; 18 
months of data post-
index prescription. 
1) Opioid shopper: ≥1 days overlapping 
opioid prescriptions, ≥2 prescribers and 
≥3 dispensing pharmacies (1 shopping 
episode) (18 months) 
A) 0.7% (n=75,215); accounted for 8.6% 
of all dispensed opioids 
2) Proportion of heavy shoppers: ≥5 
shopping episodes (18 months) 
A) 0.1% (n=9,435) 
 
*Median miles [km] travelled 
to fill opioid prescriptions (18 
months) 
Non-shoppers: 0 [0 km] 
Shoppers: 83.8 [134.9 km] 
Heavy shoppers: 199.5 
[321.1 km] 
*Median opioid dispensings 
Non-shoppers: 6 
Shoppers: 39 
Heavy shoppers: 390 
*Proportion of users with 
opioid dispensings from ≥2 
states (18 months)  
Non-shoppers: 4.2% 
Shoppers: 19.3% 
Heavy shoppers: 22.4% 
 
Dormuth10 
2012 
Canada 
(1993-1997) 
Determine if 
implementing a 
real-time 
centralized 
prescription 
network (RTCP) 
reduced rate of 
potentially 
inappropriate 
BZDs and opioid 
dispensings. 
Cohort: ≥1 opioid (O) or 
BZD dispensings for ≥30 
tablets 
A) O – Social assistance 
(N=86,704): users 
receive social assistance 
B) BZD – Social 
assistance (N=47,983): 
users receive social 
assistance  
C) O – aged ≥65 years 
(N=199,497)  
1) Proportion of inappropriate 
dispensings: ≥2 prescribers and ≥2 
dispensing pharmacies for ≥30 tablet 
dispensings (7 days)  
A) 3.2% (n dispensings not reported) 
B) 1.2% (n dispensings not reported) 
C) 0.2% (n dispensings not reported) 
D) 0.6% (n dispensings not reported) 
 
*Relative change in 
inappropriate dispensings: 
post RTCP implementation 
(30 months) 
A) -32.8%  
B) -48.6% 
C) -40.1% 
D) -42.4% 
*Absolute change in 
inappropriate dispensings 
per month 
A) -1.1%  
*RTCP implementation 
associated with large, 
immediate and sustained 
reductions in inappropriate 
opioid and BZD dispensings. 
*Inappropriate NSAIDs use 
(comparator medicine) was 
infrequent and did not 
change during this time 
period. 
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D) BZD – aged ≥65 years 
(N=150,699) 
B) -0.5% 
C) -0.3% 
D) -0.1% 
Feroni11 
2005 
France 
(Oct 2001- 
Nov 2002) 
Investigate GPs 
attitudes 
towards 
buprenorphine 
maintenance 
treatment 
(BMT) and their 
BMT patients’ 
propensity to 
doctor shop 
(opioid). 
A) Cohort (N not 
reported): BMT patients 
of 345 GPs who 
participated in a random 
telephone survey. All 
GP’s BMT patients’ data 
then matched to health 
insurance data. 
No threshold of misuse defined. *On average, BMT users 
access 3.1 prescribers in 12 
months (range: 1-13). 
*Doctor shopping was lower 
for persons starting BMT on 
≥8 mg/day, than those who 
were prescribed <8 mg/day. 
*Patients whose doctors 
always or often collaborate 
with a specialized 
network/care center had a 
higher number of 
prescriptions. 
*Doctor shopping 
correlated with high mean 
prescriptions per user and 
shorter average duration of 
BMT. 
*Socioeconomic 
characteristics strongly 
associated with doctor 
shopping: more physicians 
per km2; fewer people per 
household; higher 
unemployment or blue 
collar workers. 
Frauger12 
2009 
France 
(2001 and 
2006) 
Estimate 
clonazepam 
(BZD) deviant 
behavior, trends 
in deviant 
behavior and 
characteristics 
of deviants. 
 
A) Cohort (N=26,480): 
≥1 clonazepam 
dispensings.  
 
1) Deviant group: defined by cluster 
analysis profiling individuals by number 
of: dispensing pharmacies; prescribers; 
dispensings and total quantity dispensed 
(9 months) 
A) Deviant user: 1.1% (n=292) 
‘More deviant’ user: 0.07% (n=19) 
 
*Mean (SD) dispensing 
pharmacies (9 months)  
Deviant: 6.4 (2.8) 
More deviant: 16.6 (4.3) 
All other persons: 1.4 (0.7) 
*Mean (SD) prescribers (9 
months) 
Deviant: 4.6 (2.2);  
More deviant: 11.6 (3.7) 
All other persons: 1.5 (0.8) 
*Mean (SD) dispensing 
episodes (9 months) 
Deviant: 21.1 (8.3) 
More deviant: 65.0 (31.4) 
All other persons: 6.0 (3.0) 
*Mean (SD) sum of DDD 
dispensed (9 months) 
*Deviant group 
characteristics: younger, 
male and associated with 
higher: use of BZDs and 
buprenorphine; number of 
prescribers, dispensing 
pharmacies, deliveries and 
total DDD dispensed. 
*The prevalence of deviant 
behavior increased from 
0.9% in 2001 to 1.4% in 
2006. 
*Proportion of clonazepam 
dispensed to deviant group 
increased from 7.8% (2001) 
to 9.5% (2009).  
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Deviant: 392.1 (200.3) 
More deviant: 1379.7(1014.1) 
All other persons: 54.6 (51.3) 
Frauger13 
2011 
France 
(2005-2008) 
Describe 
patterns of 
methyl-
phenidate (CNS 
stimulant) use 
and rates of 
abuse and 
diversion.  
 
A) Cohort (N=3,574): ≥1 
methylphenidate 
dispensings. 
1) Deviant group: defined by cluster 
analysis profiling individuals by number 
of: dispensing pharmacies; prescribers; 
dispensings and total quantity dispensed 
(9 months) 
A) 1.1% (n=40) 
 
*Mean (SD) dispensing 
pharmacies (9 months) 
Deviant: 11.0 (4.9) 
All other persons: 1.3 (0.6) 
*Mean (SD) prescribers (9 
months) 
Deviant: 12.0 (4.4);  
All other persons: 1.8 (0.9) 
*Mean (SD) dispensing 
episodes (9 months) 
Deviant: 41.9 (14.7) 
All other persons: 6.4 (4.5)  
 
*Mean (SD) sum of DDD 
dispensed (9 months) 
Deviant: 1707.6 (585.3) 
All other persons: 170.5 
(150.6) 
*Proportion of deviant 
behavior increased over 
study period, peak of 2.0% 
in 2007. 
*Deviant group 
characteristics: higher 
utilization rates of BZD, AD, 
antipsychotic or opioid 
maintenance therapy. 
Fredheim14 
2009 
Norway 
(2004-2006) 
Identify 
‘problematic’ 
codeine (opioid) 
prescription 
patterns. 
 
A) Naïve users 
(N=222,929): ≥1 codeine 
dispensings in 2005. 
Excluded: prescriptions 
with incomplete 
identifiers or prescribed 
for cancer.  
B) Old users 
(N=162,261): A) and ≥1 
codeine dispensings in 
2004. 
1) High user: dispensed >365 DDD of 
codeine (12 months) 
A) 0.03% (n=64) 
B) 5.8% (n=9,384) 
•In high users: dispensed >100 DDD of 
BZDs (12 months) 
Naïve users: 29.7% (n=19) 
Old users: 50.5% (n=4,738) 
•In high users: dispensed >15 DDD of 
carisoprodol (12 months) 
Naïve users: 18.8% (n=12) 
Old users: 30.2% (n=2,838) 
•In high users: dispensed >730 DDD of 
codeine (12 months) 
Naïve users: 1.6% (n=1) 
Old users: 19.0% (n=1,786) 
*Persons with >730 DDD per 
year of codeine frequently 
co-medicated with other 
drugs including BZDs (66%) 
and carisoprodol (45%). 
*0.5% of persons prescribed 
codeine developed serious 
problematic use. 
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Gilson15 
2012 
US 
(2000-2006) 
 
Investigate if 
changes to 
prescription 
monitoring 
program 
influences:  
i) prescribing 
rate for nine 
schedule II long- 
(LA) or short 
acting (SA) 
opioids, or  
ii) incidence of 
multiple 
provider 
episodes 
(MPEs). 
A) Cohort (N not 
reported): 
inclusion/exclusion 
criteria not specified.  
Prescription level data 
(N=15,506,651) 
1) Prescriptions involved in multiple 
provider episodes (MPEs): ≥2 prescribers 
for same opioid and ≥2 dispensing 
pharmacies (30 days) 
9.6% (n prescriptions=1,488,639) 
*Prescriptions dispensed 
involving MPEs (time period 
not reported) 
SA hydromorphone: 15.2% 
SA fentanyl: 11.4% 
SA oxycodone: 10.9% 
SA morphine: 10.0% 
LA oxycodone: 8.7% 
Methadone: 8.6% 
LA morphine: 8.5% 
LA fentanyl: 8.1% 
Meperidine: 7.0% 
*Policy change increased 
rate of MPEs involving all 
opioids. 
*Replacing triplicate forms 
with a secure tamper 
resistant form increased 
prescribing rates for SA 
hydromorphone, 
meperidine, SA oxycodone. 
Prescribing rates 
unchanged for SA or LA 
fentanyl, methadone, SA or 
LA morphine and LA 
oxycodone. 
Gjerden16 
2009 
Norway 
(2004) 
Investigate use 
and potential 
abuse of 
antiparkinson 
(AP) drugs. 
Cohort (N=73,964): aged 
18-69  
A) (N=70,937) 
Dispensed any 
antipsychotic drug  
B) (N=2,771) Dispensed 
dopaminergic or 
anticholinergic AP drug 
reimbursed for 
Parkinson’s disease  
C) (N=213) Dispensed 
antipsychotic and 
evidence of Parkinson’s 
disease 
D) (N=43) Dispensed 
anticholinergic 
1) Proportion of medicine volume 
consumed by highest 1% of users: a figure 
>15% is a strong signal for medicine abuse 
(12 months) 
Biperiden: 6.2% 
BZDs: 16.5% 
Orphenadrine: 5.4% 
2) Doctor shopper: ≥3 prescribers for BZD 
tranquilizers (12 months) 
No meaningful data derived. 
 
*Maximum number of BZD-
prescribers (12 months) 
A) 8 
B) 5 
C) 3 
D) 6 
*Antipsychotic drug users 
accounted for 94% of 
anticholinergic use, 
compared to 4.3% of 
antipsychotic drug user’s 
with Parkinson's disease.  
*BZD use more frequent in 
antipsychotic drug users than 
antipsychotic drug users with 
Parkinson's disease.  
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medicine, not dispensed 
an antipsychotic, no 
evidence of Parkinson's 
disease. 
Excluded if: dispensed 
benzhexol, procyclidine 
or trihexyphenidyl. 
*Cohort D had highest rate 
of BZD concomitant use. 
Goodman17 
2005 
US 
(Jun 2000-Jul 
2002) 
Determine if a 
prescription 
review could 
identify cases of 
possible 
oxycodone ER 
abuse (opioid). 
 
A) Cohort (N not 
reported): ≥1 oxycodone 
ER dispensing from a 
Veteran’s Affairs (VA) 
facility.  
Case level data 
(N cases = 60,955) 
 
Proportion of cases meeting criteria.  
1) Dispensed large quantity: ≥480 tablets 
per prescription (20 months) 
A) 5% (n=4 cases) 
2) Multiple sites: prescription for same 
medicine filled ≥10 days early from ≥2 
facilities (25 months) 
A) 24% (n=41 cases) 
3) Multiple Veterans Integrated Service 
Networks (VISNs): prescription for same 
medicine filled ≥10 days early from ≥2 
VISNs (10 months) 
A) 15% (n=6 cases) 
4) High usage: ≥480 tablets per 
prescriptions, high dosage (320 mg daily), 
or frequent dosing intervals (every 4-6 
hours): extent of misuse not reported  
5) Early refills: ≥2 consecutive early refills 
from ≥2 providers: extent of misuse not 
reported 
6) Large total quantity: ≥480 tablets total 
per month: extent of misuse not reported 
*Cases involving 
past/present substance 
abuse diagnosis per measure 
of misuse (time period not 
reported) 
Dispensed large quantity: 3% 
(n=2 cases) 
Multiple sites: 5% (n=8 cases) 
Multiple VISNs: 5% (n=2 
cases) 
 
Doctor’s aberrant prescribing 
pattern as indicator. 
*Doctors prescribed large 
quantity: ≥480 tablets per 
prescription (20 months) 
12% (n=10 cases) 
*Multiple sites: doctor 
aberrant prescribing not 
defined (25 months) 
2% (n=3 cases) 
 
*Multiple VISNs: doctor 
aberrant prescribing not 
defined (10 months) 
2% 
*The prevalence of 
aberrant drug-related 
behavior of multiple sites 
or multiple VISNs 
decreased over the review 
periods. 
 
Hall18 
2008 
US 
(2006) 
Evaluate 
characteristics 
of persons dying 
from 
A) Cohort (N=295): died 
of unintentional drug 
poisoning according to 
death certificate in 
1) Doctor shopper: ≥5 prescribers of 
controlled substances (12 months) 
A) 21.4% (n=63) 
 
*Diverters: pharmaceuticals 
used without a prescription 
record (12 months) 
A) 63.1% (n=186) 
*Unintentional overdose 
death rate: 16.2/100,000 
*Doctor shopping 
associated with: being 
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 unintentional 
pharmaceutical 
overdose 
(controlled 
substances), 
types of drugs 
involved and the 
role of drug 
abuse in deaths.  
 
2006. Excluded: no 
autopsy performed; 
toxicology tests not 
performed by Office of 
Medical Examiner; 
overdose due 
exclusively to illicit 
drugs, over the counter 
products and/or alcohol. 
*Diverter and doctor shopper 
(12 months) 
A) 8.1% (n=24) 
*Deaths involving specific 
medicine classes (12 months) 
Opioid analgesic: 93.2% 
Psychotherapeutic: 48.8% 
Other prescription drug 
(butalbital, carisoprodol, 
cyclobenzaprine, diltiazem, 
phenytoin, promethazine): 
11.2% 
female (OR 2.2); aged 35-44 
years (OR 2.0); previous 
overdose (OR 2.8). 
*Diversion behavior 
associated with: 18-24 age 
group (OR 12.1) never 
marrying (OR 2.8); history 
of substance abuse (OR 
1.8); non-medical route of 
pharmaceutical 
administration (OR 1.9) or 
illicit drug use (OR 2.1). 
Han19 
2012 
US 
(2005-2007) 
 
Examine effect 
of individual and 
county related 
factors on use of 
multiple 
prescribers 
and/or 
pharmacies for 
prescription 
opioids. 
A) Cohort 
(N=1,057,012): ≥1 
opioid dispensings per 
year (2005 to 2007). 
Excluded if: incomplete/ 
implausible prescription; 
commercial transaction; 
non-standard route of 
administration for 
chronic pain users; drug 
use by age group not 
associated with chronic 
pain or obtaining drugs 
through office 
interactions. 
No threshold of misuse defined. *Number of prescribers (12 
months) 
A) Mean (range): 2.1 (1-158)  
1 prescriber: 50.7% 
(n=536,408) 
2-5 prescribers: 45.1% 
(n=476,843) 
≥6 prescribers: 4.1% 
(n=43,761) 
*Number of dispensing 
pharmacies (12 months) 
B) Mean (range): 1.8 (1-100) 
1 pharmacy: 59.0% 
(n=623,357) 
2-5 pharmacies: 38.9% 
(n=411,704) 
≥6 pharmacies: 2.1% 
(n=21,951) 
*Higher number of 
prescribers and dispensing 
pharmacies associated with: 
*Physician availability was 
the most robust predictor, 
i.e. as number of physicians 
increased so did number of 
prescribers and dispensing 
pharmacies.  
*Individuals who use both 
schedule II and III opioids 
visited multiple prescribers 
and multiple pharmacies 
more often than those who 
used opioids from a single 
schedule. 
*Higher use of multiple 
prescribers and pharmacies 
associated with: ethnicity, 
educational attainment, 
median household income 
and physician availability. 
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younger age (18-74), being 
female, living in a county 
with more licensed 
physicians and surgeons.  
Hartz20 
2009 
Norway 
(2004-2007) 
 
Examine 
association 
between 
disability 
pensioners using 
BZD and aspects 
of problematic 
use. 
A) Cohort (N=19,520): 
aged ≤61 years; ≥1 BZD 
dispensing; health 
survey data linked to 
national prescription 
database. Excluded if: 
reimbursed for cancer 
drugs; died/emigrated 
prior to 2004; BZD user 
at survey baseline; 
wrote trade names for 
BZD in survey; missing 
disability status. 
1) Long term user: dispensed ≥1 BZD each 
year between 2004 and 2007 (48 months) 
A) 2.2% (n=425) 
 
*In long term users, median 
BZD use was higher in 
disability pensioners (50 
DDD) than non-disability 
pensioners (20 DDD).  
*When controlling for other 
factors, long term use of BZD 
is more prevalent in disability 
pensioners than non-
disability pensioners (OR 
2.5).  
 
*Predictors of long-term 
BZD use: being female and 
increasing age. 
*Use of BZD and other 
potentially addictive drugs 
(z-drugs, opioids and 
carisoprodol) increased 
over the 4 years.  
 
Hoffman21 
2003 
US 
(1998-Mar 
2000) 
Evaluate 
effectiveness of 
physician alert 
to reduce 
patients’ 
excessive use of 
prescription 
drugs and 
decrease costs 
to the third 
party payer 
(controlled 
substances 
schedule II to 
IV). 
 
A) Control (n=89): ≥1 
alert. 
B) Excessive users 
(n=94): letter sent to 
physician; user has ≥3 
alerts in 3 months 
(alerts relate to number 
of prescribers, 
pharmacies and volume 
of drug dispensed); no 
concurrent medication 
use indicative of cancer, 
HIV infection or renal 
failure. Excluded if: 
Medicare user; <6 of 
collected data. 
1) Recurrent excessive users: ≥2 letters 
sent out to physician (6 months) 
B) 29.8% (n=28) 
 
*Number of prescribers (3 
months) 
Pre-intervention mean (SD) 
to post-intervention mean 
(SD) [% change] 
A) 5.3 (2.4) to 1.4 (2.4)  
[-22.0%]  
B) 6.4 (3.6) to 2.2 (3.3)  
[-28.0%] 
*Number of prescriptions (1 
month) 
A) 13.4 (3.5) to 3.7 (4.7)  
[-28.4%] 
B) 13.7 (6.4) to 5.0 (4.4) 
[38.1%] 
*Number of high abuse 
*Prescription drug cost (1 
month) 
A) $460.15 ($335.00) to 
$39.07 ($331.00) [-17.9%] 
B) $480.28 ($393.00) to 
$118.38 ($296.00) [-23.1%] 
*Medical cost (12 months) 
A) $8811.90 to $970 [not 
reported] 
B) $9115.96 to $1413.00 
[not reported] 
*23% of users whose 
physicians received letters 
did not show any change in 
dispensing patterns. 
*Authors attributed control 
 48 
 
Cohorts matched on 
total number of 
prescriptions and 
number of prescriptions 
with abuse potential. 
prescriptions (1 month) 
A) 5.5 (2.1) to 2.0 (2.6)  
[-33.6%] 
B) 6.0 (2.8) to 3.1 (4.6)  
[-45.5%] 
group results to ’regression 
toward the mean’.  
Katz22 
2010 
US 
(Jul 1995- Jun 
2006) 
 
Evaluate trends 
in schedule II 
opioid 
prescribing and  
dispensing. 
 
 
A) Cohort (N=562,592): 
≥1 opioid dispensings in 
2006. Excluded if: entry 
missing prescriber 
number, date filled, 
prescription number, 
quantity, national drug 
code, days of supply, 
valid date of birth or 
customer ID.  
 
 
1) Questionable activity: ≥3 prescribers 
and ≥3 dispensing pharmacies (12 
months) 
% persons; % prescriptions; % dosage 
units 
A) 1.6% (n=8,797); 7.7% (n=112,381); 
8.5% (n=7,622,840) 
2) Preferred indicator: Questionable 
activity: ≥4 prescribers and ≥4 dispensing 
pharmacies (12 months) 
A) 0.5% (n=2,748); 3.1% (n=45,102); 3.1% 
(n=2,805,613) 
3) Questionable activity: ≥5 prescribers 
and ≥5 dispensing pharmacies (12 
months) 
A) 0.2% (n=1,149); 1.5% (n=22,075); 1.4% 
(n=1,247,666) 
4) ≥1 early refills: two consecutive 
prescriptions for same drug with number 
of days between prescriptions being 
>10% lower than number of days of 
supply in first prescription, i.e. if 
prescription for 30 days, second 
prescription filled <27 days after first 
dispensing) (time period varied based on 
length of prescription) 
Mean (SD): 0.1 (0.67) 
A) 6.9% (n=38,819) 
*Number of prescribers (12 
months) 
A) Mean (SD): 1.4 (0.93) 
1 prescriber: 78.9% 
(n=443,956) 
2 prescribers: 13.4% 
(n=75,191) 
3 prescribers: 4.4% 
(n=24,919) 
4 prescribers: 1.8% (n=9,980) 
5 prescribers: 0.8% (n=4,274) 
6 prescribers: 0.3% (n=1,887) 
7 prescribers: 0.2% (n=1,025) 
8 prescribers: 0.1% (n=543) 
9 prescribers: 0.1% (n=296) 
≥10 prescribers: 0.1% 
(n=520) 
*76.9% of users with one 
prescriber accessed one 
pharmacy; 0.1% of users with 
one prescriber accessed ≥4 
dispensing pharmacies. 
*Among persons using ≥5 
prescribers, 14.1% used ≥4 
dispensing pharmacies. 
*Among persons using ≥10 
prescribers, 69.2% used ≥4 
dispensing pharmacies. 
*Number of dispensing 
pharmacies (12 months) 
A) Mean (SD): 1.1 (0.52) 
1 pharmacy: 90.6% 
(n=509,818) 
2 pharmacies: 6.9% 
(n=38,865) 
3 pharmacies: 1.6% 
(n=8,870) 
4 pharmacies: 0.5% 
(n=2,917) 
5 pharmacies: 0.2% 
(n=1,138) 
6 pharmacies: 0.1% (n=464) 
7 pharmacies: 0.04% 
(n=248) 
8 pharmacies: 0.02% 
(n=108) 
9 pharmacies: 0.01% (n=76) 
≥10 pharmacies: 0.02% 
(n=87) 
*Rate of questionable 
activity increased between 
1996-2002 and decreased 
between 2002-2006, 
despite an increase in 
opioid prescribing.  
*SA oxycodone was the 
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 *11% of total population 
received ≥1 schedule II 
opioid in 2006.  
opioid most associated 
with questionable activity. 
Logan23 
2013 
US 
(2009) 
Determine 
prevalence of 
opioid misuse 
and the 
inappropriate 
prescription 
practices by 
emergency 
department (ED) 
providers. 
 
A) Cohort (N=400,288): 
aged 18-64; ≥1 opioids 
dispensed same day as 
ED visit that was not 
part of a hospital 
admission. Excluded if: 
incomplete information; 
claims for services which 
could not render 
opioids; tests not 
confirming diagnostic 
information; not 
continuously enrolled in 
health plan for 2009; or 
treatment for cancer 
pain determined by ICD-
9 diagnosis for cancer. 
1) ≥2 overlapping ED opioid prescriptions: 
overlapping by ≥7 days (12 months) 
A) 2.1% (n=8,229) 
2) Overlapping ED opioid and BZD 
prescriptions: overlapping by ≥7 days (12 
months) 
A) 1.0% (n=3,867) 
3) ≥1 incidents of LA/ER opioid dispensed 
for acute pain condition (12 months) 
A) 0.1% (n=565) 
4) Dispensed high opioid doses from ED: 
daily dose of ≥100 morphine milligram 
equivalent (12 months) 
A) 7.8% (n=31,117) 
 
*Prescriptions overlapped 
with another LA opioid 
prescriptions: overlapping by 
≥7 days (12 months) 
A) 14.6% 
*≥2 opioid-related ED 
presentations (12 months) 
A) 8% (n=32,024) 
*Number of ED opioid 
prescriptions (12 months) 
A) 1 prescription: 91.0% 
2 prescriptions: 7.0% 
≥3 prescriptions: 2.0% 
*A higher proportion of 
females (11.5%) had at 
least one indicator of 
potentially inappropriate 
prescribing or misuse, 
compared to males (9.0%). 
Mailloux24 
2010 
US 
(Jul 1998– 
Aug 1999) 
Identify persons 
abusing 
controlled 
substances 
(opioids, BZDs, 
and CNS 
stimulants) 
through a 
decision support 
tool. Abuse 
determination 
based on 
number of 
A) Intermediate abusers 
(N=85): letter sent to 
physician to alert them 
to their patients’ 
behavior 
B) Abusers (N=39): no 
change from 
‘intermediate abuser’ 
behavior within 6 
months, individual is 
‘locked-in,’ i.e. for 2 
years one prescriber and 
one dispensing 
1) Shopping behavior: medicine obtained 
by ‘multiple providers and pharmacies’ (6 
and 2 months) 
i) Mean (SD) days of overlapping 
prescriptions (6 months) 
A) 155.8 (103.1) 
B) 768.2 (609.2) 
ii) Mean (SD) days of overlapping 
prescriptions (2 months) 
A) 70.8 (55.4) 
B) 350.8 (246.1) 
2) Early refill: same medication obtained 
from one physician and multiple 
*Mean (SD) duplicate 
prescription score: number of 
duplicate prescriptions 
(controlled substance 
obtained from different 
prescribers/pharmacies on 
the same day) (time period 
not reported)  
A) 0.3 (0.6) 
B) 1.2 (1.5) 
*Mean (SD) dispensing 
pharmacies (time period not 
reported) 
*Mean controlled 
substances claims (time 
period not reported) 
A) 22.3 (10.4) 
B) 48.7 (18.6) 
*Overall the classification 
rate is 95.3%. (Sensitivity: 
87.2%, specificity: 96.5%.) 
*Number of dispensing 
pharmacies was the best 
predictor of abuse of 
controlled substances. 
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prescribers, 
pharmacies, 
volume of drug 
dispensed and 
medical 
diagnosis. 
pharmacy. Excluded if: 
‘lock-in’ required 
informed consent, part 
of mental health 
commitment or 
condition of 
probation/parole. 
 
pharmacies within 50% of the days’ 
supply of the first prescription (6 and 2 
months) 
i) Mean (SD) episodes (6 months) 
A) 1.9 (2.5) 
B) 5.9 (13.4) 
ii) Mean (SD) episodes (2 months) 
A) 0.6 (1.0) 
B) 3.1 (6.6) 
A) 4.2 (1.8) 
B) 9.9 (4.3) 
*Mean (SD) prescribers (time 
period not reported) 
A) 4.8 (2.7) 
B) 12.2 (6.5) 
 
Martin25 
2011 
US 
(2000-2005) 
Report rates of 
opioid misuse, 
discontinuation 
(≥182 days of no 
opioid use), and 
identify factors 
associated with 
discontinuation. 
 
A) Commercially 
insured (N=23,41): ≥1 
chronic opioid use 
episode, i.e. >90 days of 
opioids supplied in any 6 
month period between 
Mar 2001-Dec 2004, 
continuous enrolment 
for 12 months pre-and 
post-index date (first 
opioid dispensing), 
identified in HealthCore 
dataset.  
B) Publically insured 
(N=6,848): A) but 
identified in Arkansas 
Medicaid.  
1) Opioid misuse score: based on excess 
days supplied short- and long-acting 
opioids, number of dispensing 
pharmacies, and number of prescribers (6 
months) 
Score 0-1: no misuse 
A) 83.2% (n=19,474) 
B) 87.7% (n=6,003) 
Score 2-3: possible misuse 
A) 14.5% (n=3,399) 
B) 10.9% (n=747) 
Score ≥4: probable misuse 
A) 2.2% (n=523) 
B) 1.4% (n=98) 
 
*Prevalence of opioid abuse 
disorder (time period not 
reported) 
A) 0.6% (n=130) 
B) 0.5% (n=36) 
*Approximately 1/7 persons 
potentially misuse opioids. 
*Commercially insured 
cohort: persons with possible 
or probable opioid misuse 
were 20% less likely to 
discontinue opioids than 
those with no indication of 
opioid misuse. 
 
McDonald26 
2013 
US 
(2008) 
Estimate 
prevalence of 
users obtaining 
opioid 
prescriptions 
from different 
physicians. 
A) Cohort (N=’13.6 
million’): ≥1 opioid 
dispenings in first 60 
days of 2008.  
 
1) Extreme outlying population: 
determined by latent class analysis based 
on method of payment, gender, age (10 
months) 
A) 0.7% (n≈95,200), accounting for 1.9% 
of dispensed medicine. 
 
*Number of prescribers for 
57% of users dispensed an 
opioid after first 60 days of 
2008 (10 months) 
1 prescriber: 31%  
2 prescribers: 14% 
3-4 prescribers: 8.6% 
*Users ’aged mid to late 
20s were 10 times more 
likely to fit the extreme 
profile than users double 
their age’. 
*In the extreme 
population, the average 
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(inferred)  
5-9 prescribers: 3% 
10-19 prescribers: 0.4% 
≥20 prescribers: 0.04% 
*Mean number of prescribers 
for extreme population (10 
months): 10.4 
number of prescribers 
increased with age until age 
40, after which it declined. 
Nordmann27 
2013 
France 
(2008) 
Describe and 
compare opioid 
abuse using 
doctor shopping 
to estimate 
abuse in three 
French regions. 
 
A) PACA (N=885,941): 
≥1 opioid dispensings;  
resident of Provence-
Alpes-cote d’Azur 
(PACA) 
B) RA (N=945,102): A) 
except resident of 
Rhone Alps (RA). 
C) MP (N=386,834): A) 
except resident of Midi-
Pyrenees (MP). 
D) Entire cohort (N= 
2,217,877): A) + B) + C) 
1) Doctor shopping quantity (DSQ): 
amount of excess drug dispensed by 
overlapping prescriptions written by ≥2 
prescribers (12 months) 
A) 213.3 DDD/1000 population 
B) 115.1 DDD/1000 population 
C) 106.2 DDD/1000 population 
D) 150.5 DDD/1000 population 
Drug class: DSQ (DDD/1000 population) 
(% of all dispensed drug) 
Weak opioid analgesics: 75.5 (50.2%) 
OMT opioids: 55.3 (36.7%) 
Strong opioid analgesics: 19.7 (13.1%) 
2) Doctor shopping indicator (DSI): 
proportion of total drug dispensed 
obtained by overlapping prescriptions 
from ≥2 prescribers (12 months). DSI <1% 
is not a signal for abuse. 
Drug class: DSI 
OMT: 6.2% 
Strong opioid analgesics: 5.0% 
Weak opioid analgesics: 1.1% 
*DSQ by opioid (12 months) 
Drug: DSQ (DDD/1000 
population)  
D) Buprenorphine (OMT): 
50.3 
Dextropropoxyphene: 27.6 
Codeine: 24.1 
Tramadol: 23.3 
Morphine: 17.8 
Methadone: 4.9 
Oxycodone: 1.5 
Dihydrocodeine: 0.5 
Buprenorphine (analgesic): 
0.2 
Hydromorphone: 0.2 
 
*Specific opioids with 
DSI≥1% (12 months) 
D) Buprenorphine (OMT): 
8.0% 
Morphine: 5.5% 
Dihydrocodeine: 3.7% 
Buprenorphine (analgesic): 
2.9% 
Oxycodone: 2.7% 
Codeine: 2% 
Methadone: 1.9% 
Hydromorphone: 1.8% 
Tramadol: 1.1% 
*DSQ was 2-fold higher in 
PACA than RA and MP. 
*Tramadol and 
dextropropoxyphene DSI 
show a very low signal of 
abuse. 
Parente28 
2004 
US 
(2000) 
Develop 
indicators of 
controlled 
substance 
A) Cohort 1 
(N=2,927,237).  
B) Cohort 2 
(N=782,800). 
1) ≥6 prescribers of same drug (time 
period not reported) 
A) 0.2% (n=6,148) 
B) 0.3% (n=1,957) 
*These measures are not a 
direct measure of misuse, 
but direct attention to 
potential problems to 
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misuse for 
general 
population 
(excluding 
persons with ≥3 
prescriptions for 
injectable opioid 
without a cancer 
diagnosis in 12 
months and 
persons 
dispensed a BZD 
or opioid with a 
substance abuse 
diagnosis) 
 
Inclusion/exclusion 
criteria not specified. 
 
 
2) ≥4 dispensing pharmacies for same 
drug (time period not reported) 
A) 0.1% (n=3,806) 
B) 0.1% (n=1,096) 
3) ≥4 prescriptions of carisoprodol (6 
months) 
A) 0.1% (n=3,805) 
B) 0.1% (n=862) 
4) Continuous overlap of ≥2 different BZDs 
for ≥90 days (time period not reported)  
i) when 1 BZD is alprazolam 
A) 0.1% (n=1,757) 
B) 0.1% (n=548) 
ii) when 1 BZD is clonazepam 
A) 0.01% (n=147) 
B) 0.01% (n=58) 
iii) when 1 BZD is diazepam 
A) 0.003% (n=88) 
B) 0.004% (n=32) 
5) ≥4 grams/day of acetaminophen (time 
period not reported) 
A) 0.03% (n=878) 
B) 0.01% (n=79) 
6) ≥2 prescriptions for meperidine 
hydrochloride with >2 days’ supply (time 
period not reported) 
A) 0.02% (n=585) 
B) 0.02% (n=157) 
7) ≥4 prescriptions of butorphanol (6 
months) 
A) 0.02% (n=585) 
B) 0.02% (n=157) 
8) Overlap of ≥2 different sustained 
determine if intervention is 
needed. 
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release or LA opioids for ≥90 consecutive 
days (time period not reported) 
A) 0.001% (n=30) 
B) 0.001% (n=8) 
Pauly29 
2011 
France 
(2006) 
Compare two 
methods to 
measure deviant 
behavior when 
obtaining high 
dosage 
buprenorphine 
(HDB) (opioid). 
 
A) Cohort (N=6,519): ≥1 
dispensing of HDB. 
1) Deviant persons: defined by cluster 
analysis profiling individuals by number 
of: dispensing pharmacies; prescribers; 
dispensings and total quantity dispensed 
(9 months).  
A) 6.0% (n=390) 
‘More deviant’ persons: 0.3% (n=21) 
2) Proportion of dispensed HDB obtained 
by DSI: 
Deviant: 40% (i.e. 60% not obtained by 
DSI) 
More deviant: 72% (i.e. 18% not obtained 
by DSI) 
Entire cohort: 13.2% 
*Mean (SD) prescribers (9 
months) 
Deviant: 6.5 (2.2) 
More deviant: 16.4 (5.7) 
*Mean (SD) dispensing 
pharmacies (9 months) 
Deviant: 8.2 (3.3) 
More deviant: 27.5 (9.5) 
*Mean (SD) dispensings (9 
months) 
Deviant: 36.9 (16.7) 
More deviant: 90.0 (32.0) 
* Mean (SD) total quantity 
dispensed (mg) (9 months) 
Deviant: 6,815 (4,462) 
More deviant: 33,720 
(14,432) 
*Deviant group are: 
younger, male, dispensed a 
higher proportion of 
flunitrazepam, 
bromazepam, clonazepam 
and ADs. 
Pauly30 
2011 
France 
(2008) 
Analyze and 
compare 
diversion and 
abuse of 14 
BZDs through a 
multi-indicator 
approach. 
 
A) Cohort (N not 
reported): ≥1 BZD 
dispensings. 
 
1) Deviant persons: defined by cluster 
analysis profiling individuals by number 
of: dispensing pharmacies; prescribers; 
dispensings and total quantity dispensed 
(9 months). 
BZD with highest % of deviant users:  
Flunitrazepam: 9.1% 
2) Doctor shopping indicator (DSI): 
proportion of total drug dispensed 
obtained by DSQ: amount of excess drug 
obtained by overlapping prescriptions 
and ≥2 prescribers (12 months).  
BZD with highest DSI: 
Flunitrazepam: 27.0% 
*Proportion of deviant users 
per BZD: 
Oxazepam: 0.4% 
Clonazepam: 0.3% 
Diazepam: 0.3% 
Zolpidem: 0.3% 
Bromazepam: 0.3% 
Lormetazepam: 0.2% 
Clorazepate: 0.2% 
Alprazolam: 0.2% 
Lorazepam: 0.2% 
Zopiclone: 0.1% 
Prazepam: 0.04% 
Tetrazepam: 0.03% 
Nordazepam: 0.03% 
*BZDs with DSI≥1%: rate of 
<1% does not constitute a 
signal for abuse (12 
months) 
Clonazepam: 2.6% 
Zolpidem: 2.5% 
Oxazepam: 2.3% 
Diazepam: 2.2% 
Alprazolam: 1.7%  
Bromazepam: 1.7% 
Lormetazepam: 1.5% 
Lorazepam: 1.3% 
Clorazepate: 1.1% 
Zopiclone: 1.1% 
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Pauly31 
2012 
France 
(2006-2008) 
Compare doctor 
shopping 
indicator (DSI) 
across 14 BZDs 
and 10 opioids 
[prescribed for 
analgesic or 
opioid 
maintenance 
treatment 
(OMT)]. 
A) Cohort (N not 
reported): 
inclusion/exclusion 
criteria not specified. 
1) DSI: proportion of total drug dispensed 
obtained by DSQ (DSQ: amount of excess 
drug obtained by overlapping 
prescriptions from ≥2 prescribers) (time 
period not reported).  
DSI <1% is not a signal for abuse. 
Drug with highest DSI: 
Buprenorphine (OMT): 12.5% 
*Other drugs with DSI≥1% 
(time period not reported) 
Opioid (OMT): 7.2% 
Morphine: 6.2% 
Buprenorphine (analgesic): 
3.9% 
Methadone: 3.3% 
BZD: 1.9% 
Oxycodone: 1.9% 
*BZDs are prescribed at a 
high rate but have a low 
rate of abuse/diversion.  
*Opioids (OMT) prescribed 
at low rate but have a high 
level of abuse/diversion. 
Pearson32 
2006 
US 
(1988-1995) 
Examine impact 
of the triplicate 
prescription 
program (TPP) 
on potentially 
problematic BZD 
use by race. 
 
A) Entire cohort 
(N=124,867): ≥19 years; 
Medicaid enrollee for 
≥10 out of 12 months 
prior to TPP; dispensed 
≥1 BZDs. (B+C+D+E) 
Cohort stratified by 
predominant racial 
neighborhood 
composition  
B) White (N=45,222) 
C) Mixed (N=43,520) 
D) Black (N=12,054) 
E) Hispanic (N=24,071) 
 
 
1) Pharmacy hoppers: dispensed same 
BZD from ≥2 pharmacies (7 days)  
A) 1.6% (n=1,955) 
B) 1.3% (n=588) 
C) 1.7% (n=740) 
D) 1.4% (n=169) 
E) 1.9% (n=458) 
2) Problematic use of BZD: BZD use was 
>2 times MRDD OR duration of BZD 
treatment >120 days 
A) 40.2% (n=50,197) 
3) Any potentially problematic BZD use: (1 
or 2) pharmacy hopper or problematic 
use of BZD  
A) 42.8% (n=53,444) 
B) 51.6% (n=23,335) 
C) 41.1% (n=17,887) 
D) 34.5% (n=4,159) 
E) 33.7% (n=8,112) 
*After introduction of TPP 
there was a sudden and 
sustained reduction in BZD 
use and potentially 
problematic use in all New 
York neighborhoods. 
*Across all practices and 
pharmacy locations black 
enrollees were most likely, 
white enrollees least likely, 
to experience reductions in 
access to BZDs. 
*’>83%’ of baseline 
pharmacy hoppers 
discontinued post-TPP.  
 
 
 
 
Peirce33 
2012 
US 
Compare doctor 
and pharmacy 
shopping 
A) “Living” persons 
cohort (N=1,049,205): 
≥18 years; dispensed ≥1 
1) Pharmacy shopper: ≥4 dispensing 
pharmacies (6 months) 
A) 1.3% (n=13,619) 
*Pharmacy shoppers (entire 
cohort) with ≥4 prescriptions 
dispensed (6 months) 
*86% of decedent cohort 
deaths were due to a 
controlled substance. 
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(Jul 2005-
2007) 
behaviors 
between 
deceased and 
living persons, 
and identify 
factors that 
predict a drug-
related death 
(controlled 
substances). 
 
schedule II-IV controlled 
substance between Jul 
2005-Dec 2007.  
B) Decedent cohort 
(N=698): A) and death 
recorded as drug-
related by the medical 
examiner in the Forensic 
Drug Database. 
C) Entire cohort 
(N=1,049,903): A) + B) 
B) 17.5% (n=122) 
C) 1.3% (n=13,741) 
•In pharmacy shoppers (entire cohort), 
proportion of doctor shoppers (6 months) 
55.6% (n=7,640)  
2) Doctor shopper: ≥4 prescribers (6 
months) 
A) 3.6% (n=37,594) 
B) 25.2% (n=176) 
C) 3.6% (n=37,770) 
•In doctor shoppers (entire cohort), 
proportion of pharmacy shoppers (6 
months) 
20.2% (n=7,640) 
90.0% (n=12,361) 
*Pharmacy shoppers (entire 
cohort) with ≥3 controlled 
substances dispensed (6 
months) 
50.3% (n=6,918) 
*Doctor shoppers with ≥4 
prescriptions dispensed (6 
months) 
82.6% (n=31,180) 
*Doctor shoppers (entire 
cohort) with ≥3 controlled 
substances dispensed (6 
months) 
Doctor shopper: 49.2% 
(n=18,566) 
*Predictors of drug-related 
death: greater number of 
prescriptions dispensed 
(not defined, OR 1.14); 
dispensed an opioid (OR 
3.40); dispensed a BZD (OR 
7.21); dispensed both BZD 
and opioid (OR 14.92); 
pharmacy and doctor 
shopper (OR 3.59); 
pharmacy shopper alone 
(OR 3.8); doctor shopper 
alone (OR 2.03). 
*Older age (not defined) 
was less associated with 
drug-related death (OR 
0.96). 
Pradel34 
2004 
France 
(Sep 1999-
Dec 2000) 
 
Assess rates of 
doctor shopping 
for high dosage 
buprenorphine 
(HDB) 
maintenance 
therapy (opioid) 
A) Cohort (N=2,587): ≥1 
HDB dispensings; >31 
days of follow up. 
Excluded if: insufficient 
number of prescriptions. 
1) Doctor shopper: overlapping 
prescriptions and ≥2 prescribers (16 
months) 
A) 39.5% (n=1,023) 
•In doctor shoppers: persons dispensed 
≥16 mg per day of HDB (16 months)  
8.5% (n=87) 
*Quantity HDB obtained by 
doctor shoppers:  
18.7% (1,802,806 mg) 
*Delivered doses of HDB for 
doctor shoppers (mg/day):  
2.2 mg 
 
Pradel35 
2009 
France 
(2000, 2002, 
2004, 2005) 
Assess the 
prevalence of 
doctor shopping 
for HDB (opioid) 
and evaluate the 
impact of the 
prescription 
monitoring 
program (PMP) 
A) Cohort (N=21,911): 
≥2 HDB dispensings in 
35 days. 
1) Doctor shopping quantity (DSQ): 
amount of excess drug dispensed by 
overlapping prescriptions written by ≥2 
prescribers (12 months). 
Range: 631 (2000) to 1151 (2004) grams  
2) Doctor shopping indicator (DSI): 
proportion of total drug dispensed 
obtained by DSQ (12 months)  
Range: 14.9% (2000) to 21.7% (2004) 
*Impact of PMP (last 6 
months of 2004 to last 6 
months of 2005):  
DSQ: 1151 grams to 858 
grams. 
DSI: 21.7% to 16.9%. 
*At any given time period, 
approximately 200 patients 
(‘<8%’) obtained 80% of HDB. 
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for maintenance 
treatment. 
*75% of users did not have a 
DSQ. 
Pradel36 
2010 
France 
(2003) 
Assess abuse 
potential of 
eight BZDs (14 
formulations) 
via doctor 
shopping. 
 
A) Cohort (N=128,230): 
≥1 BZD dispensings.  
 
1) Doctor shopping quantity (DSQ): 
amount of excess drug dispensed by 
overlapping prescriptions written by ≥2 
prescribers (12 months).  
Total BZD DSQ: 361,428 DDD 
BZD with highest DSQ:  
Flunitrazepam 1 mg: 108,727 DDD 
2) Doctor shopping indicator (DSI): 
proportion of total drug dispensed 
obtained by DSQ. DSI<1% does not 
constitute a signal for abuse (12 months)  
BZD with highest DSI: 
Flunitrazepam 1 mg: 42.8% 
 
*Volume of drug obtained by 
DSQ (DDD) (12 months) 
Bromazepam 6 mg: 56,913  
Clorazepate 50 mg: 36,335  
Alprazolam 0.5 mg: 14,852  
Diazepam 10 mg: 11,125  
Lorazepam 2.5 mg: 10,360  
Clonazepam 2 mg: 7,752  
Lorazepam 1 mg: 4,222  
Tetrazepam 50 mg: 2,910  
Clorazepate 10 mg: 2,645  
Alprazolam 0.25 mg: 1,308  
Diazepam 5 mg: 1,110  
Clorazepate 5 mg: 401  
Diazepam 1 mg: 200  
*Drugs with DSI ≥1% (12 
months)  
Diazepam 10 mg: 3.2% 
Clorazepate 50 mg: 2.7% 
Alprazolam 0.5 mg: 1.9% 
Bromazepam 6 mg: 1.9% 
Clonazepam 2 mg: 1.8% 
Lorazepam 2.5 mg: 1.1% 
*For BZDs with multiple 
formulations, highest doses 
always had higher DSI/DSQ 
than lower doses. 
*BZDs by abuse potential:  
Very high: flunitrazepam 1 
mg;  
High: diazepam 10 mg, 
clorazepate 50 mg;  
Intermediate: alprazolam 
0.5 mg, bromazepam 6 mg, 
clonazepam 2 mg; 
Low: alprazolam 0.25 mg; 
clorazepate 5-10 mg; 
diazepam 1-5 mg; 
lorazepam 1-2.5 mg; 
tetrazepam 50 mg. 
 
Rice37 
2012 
US 
(2007-2009) 
Identify user 
characteristics 
and behavior 
associated with 
diagnosed 
opioid abuse. 
 
Cohort (N=821,916): 
aged 12-64 years; ≥1 
opioid dispensings; 
continuously eligible in 
12 months prior to index 
date.  
Cohort stratified by 
opioid abuse diagnosis. 
1) ≥1 early refills: prescription opioid refill 
occurred with >25% of the days’ supply 
remaining on the previous prescription 
for the same active ingredient (12 
months) 
A) 38.4% (n=2,449) 
B) 4.1% (n=33,343) 
 
*Mean (SD) dispensing 
pharmacies (12 months) 
A) 2.4 (2.3) 
B) 0.7 (0.9) 
*Mean (SD) prescribers (12 
months) 
A) 3.2 (3.5) 
B) 0.8 (1.3) 
*Abusers more likely to 
have filled opioid 
prescriptions previously (IR 
or ER). 
*Predictors of ‘abusers’: 1-
5 prior opioid prescriptions 
(OR 2.23); 6 prior opioid 
prescriptions (OR 6.85); ≥1 
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A) Abusers (N=6,380): 
ICD-9-CM code related 
to opioid dependence or 
poisoning in patient 
history 
B) All other individuals 
(N=815,536) 
 
*Mean (SD) prescriptions (12 
months) 
A) 13.3 (13.1) 
B) 1.9 (4.5) 
*Mean (SD) opioids 
prescribed (12 months) 
A) 3.7 (3.7) 
B) 0.9 (1.4) 
*Mean (SD) active 
ingredients consumed in 
opioid prescriptions (12 
months) 
A) 1.9 (1.3) 
B) 0.7 (0.9) 
*Prior use of propoxyphene 
(OR 0.73) or hydrocodone 
(OR 0.70) associated with a 
reduced probability of abuse 
when controlling for other 
factors.  
prior prescription for 
buprenorphine (OR 51.75) 
or methadone (OR 2.97); ≥1 
diagnosis of non-opioid 
drug abuse (OR 9.89), 
mental illness (OR 2.45) or 
hepatitis (OR 2.36); family 
member diagnosis with 
opioid abuse (OR 3.01).  
*The finding that abusers 
were more likely to receive 
prescriptions from multiple 
providers was not 
significant when controlling 
for other factors. 
Ross-
Degnan38 
2004 
US 
(1988-1990) 
 
Evaluate the 
impact of a 
triplicate 
prescription 
program (TPP) 
on problematic 
and non-
problematic BZD 
use and on use 
of potential 
substitute drugs. 
 
Cohort: ≥19 years; 
reside in New York or 
New Jersey; 
continuously enrolled in 
Medicaid for ≥10 out of 
12 months for 1988-
1990; ≥1 BZD 
dispensings. Excluded if: 
reside in nursing home 
for >1 month. 
A) Baseline New York 
(N=25,399) 
B) Baseline New Jersey 
1) BZD treatment (>120 days) 
A) 40.3% (n=10,236) C) 41.9% (n=4,579) 
B) 37.5% (n=10,073) D) 40.1% (n=10,793) 
2) Excessive dose: average daily dose >2 
times MRDD (Various) 
A) 6.7% (n=1,702) C) 9.2% (n=1,006) 
B) 7.2% (n=1,934) D) 6.2% (n=1,669) 
3) Concurrent use of 2 LA BZD in same 
class (120 days)  
A) 1.8% (n=458) C) 1.1% (n=121) 
B) 1.2% (n=323) D) 1.0% (n=270) 
4) Concurrent use of 2 SA BZD in same 
class (120 days ) 
*Continuous use (>330 days) 
and no seizure or panic 
diagnosis (Various) 
A) 16.2% (n=41,15) C) 15.7% 
(n=1,716)  
B) 13.7% (n=3,680) D) 16.9% 
(n=4,549) 
*Existence of any 
‘problematic’ behavior: 
outcome measures 1-6 and 
continuous use (>330 days) 
and no seizure or panic 
diagnoses (Various) 
*Pharmacy hopping greatly 
reduced in New York with a 
similar reduction for both 
potentially problematic and 
non-problematic BZD use. 
*The TPP appears to have 
encouraged deliberate 
discontinuation of BZD 
therapy rather than 
reducing problems in use. 
*More people in New York 
who used BZDs 
appropriately were 
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(N=26,860) 
C) Post-TPP 
implementation New 
York (N=10,928) 
D) Post-TPP New Jersey 
(N=26,914): TPP was not 
implemented in New 
Jersey. 
 
MRDD: 10 DME/day >65 
years; 20 DME/day for 
<65 years. 
A) 3.7% (n=940) C) 2.5% (n=274) 
B) 4.2% (n=1,129) D) 4.5% (n=1,212) 
5) Receipt of ≥4 different BZDs (120 days) 
A) 1.7% (n=432) C) 0.6% (n=66) 
B) 1.9% (n=511) D) 1.9% (n=512) 
6) Pharmacy hopping: dispensed same 
BZD from ≥2 pharmacies (7 days) 
A) 7.7% (n=1,956) C) 3.7% (n=405) 
B) 3.8% (n=1,090) D) 3.9% (n=1,050) 
7) Receipt of a long half-life BZD for 
person aged >65 years (Various) 
A) 56.1% (n unclear) C) 51.3% (n unclear) 
B) 52.6% (n unclear) D) 48.6% (n unclear) 
A) 42.8% (n=10,871) C) 
45.1% (n=4,929) 
B) 40.1% (n=10,771) D) 
42.0% (n=11,304) 
*After TPP, there was a 
sudden and sustained 
reduction in BZD use in New 
York (-54.8%), with no 
changes in New Jersey.  
 
affected by the policy, i.e. 
young AFDC women (Aid to 
Families with Dependent 
Children), living in low-
income areas or high 
minority areas.  
 
Rouby39 
2012 
France 
(2005) 
Assess the 
extent of 
tianeptine abuse 
compared to 
other 
antidepressants 
(ADs) and 
BZDs/Z-drugs. 
 
A) AD cohort 
(N=410,525): ≥1 AD 
dispensings.  
B) BZD/Z-drug cohort 
(N=663,107): ≥1 BZD/Z-
drug dispensings. 
1) Doctor shopping quantity (DSQ): 
amount of excess drug dispensed by 
overlapping prescriptions written by ≥2 
prescribers (12 months). 
Drug with highest DSQ: 
A) Tianeptine: 96,183 DDD 
B) Zolpidem: 499,010 DDD 
2) Doctor shopping indicator (DSI): 
proportion of total drug dispensed, 
obtained by DSQ (12 months). DSI ≥1% is 
a signal for abuse. 
Drug with highest DSI: 
A) Tianeptine: 2.0%  
B) Flunitrazepam: 30.2% 
*Volume of drug obtained via 
DSQ (DDD) (12 months) 
A) Paroxetine: 58,738  
Fluoxetine: 52,383  
Venlafaxine: 36,483  
Mianserin: 15,344  
Amitriptyline: 12,102  
Mirtazapine: 10,285  
Milnacipran: 4,417  
B) Flunitrazepam: 436,647 
Bromazepam: 379,785 
Oxazepam: 109,239 
Clonazepam: 59,996 
Diazepam: 47,339 
*Drugs with DSI≥1% (12 
months) 
A) Mianserin 1.0% 
B) Clonazepam: 3.0% 
Zolpidem: 2.2%  
Oxazepam: 2.1% 
Diazepam: 2.0%  
Bromazepam: 2.0% 
Seal40 
2012 
US 
(Oct 2005-
Dec 2010) 
Investigate the 
effect of mental 
health disorders 
on risk of 
adverse clinical 
outcomes 
Cohort (N=141,209): 
Iraq or Afghanistan 
veteran who entered VA 
database between Oct 
2005-Dec 2008; within 
12 months of entry 
1) ≥1 early refill: obtaining the same 
opioid prescription >7 days before the 
end of the previous prescription (12 
months) 
A) 20.4% (n=914) 
B) 33.8% (n=2,701) 
*Adverse clinical outcomes 
for opioid users (12 months) 
i) Opioid-related accidents 
and overdoses: 
A) 0.02% (n=1) 
B) 0.4% (n=29) 
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associated with 
high use of 
prescription 
opioids. 
received a non-cancer 
pain diagnosis (ICD-9-
CM code); ≥1 opioid 
dispensings for ≥20 
consecutive days.  
Stratified by mental 
health diagnosis (ICD-9-
CM code). 
A) No mental health 
diagnosis (n=4,488)  
B) Mental health 
diagnosis including 
PTSD (n=7,983) 
C) Mental health 
diagnosis excluding 
PTSD (n=3,205) 
D) Entire cohort  
(N=15,676): A) + B) + C)  
C) 30.6% (n=980) 
D) 29.3% (n=4,595) 
2) Highest quintile for opioid dose (12 
months) 
A) 15.9% (n=712) 
B) 22.7% (n=1,813) 
C) 19.2% (n=615) 
D) 20.0% (n=3,140) 
3) Concurrent use of ≥2 types of opioids: 
>7 days of overlap (30 days) 
A) 10.7% (n=478) 
B) 19.8% (n=1,581) 
C) 17.3% (n=553) 
D) 16.7% (n=2,612) 
4) Concurrent use of ≥2 types of sedative 
hypnotics: >7 days of overlap (30 days) 
A) 7.6% (n=343) 
B) 40.7% (n=3,251) 
C) 25.0% (n=802) 
D) 28.0% (n=4,396) 
5) Median duration of opioid use ≥2 
months (12 months) 
A) 42.7% (n=1,916) 
B) 63.2% (n=5,047) 
C) 57.0% (n=1,828) 
D) 56.1% (n=8,791) 
C) 0.2% (n=7) 
D) 0.2% (n=37) 
*Prevalence of all adverse 
clinical outcomes (wounding, 
alcohol injury, self-inflicted 
injury or violence) was 
greater for those prescribed 
an opioid. 
*Veterans with a mental 
health diagnosis were more 
likely to receive an opioid for 
pain than persons without a 
mental health diagnosis, and 
likelihood increased if the 
diagnosis included PTSD. 
*Veterans with PTSD were 
more likely to receive a 
sedative. 
Simoni-
Wastila41 
2004 
US 
(1988-1990, 
1995) 
 
Assess the effect 
of New York 
triplicate 
prescription 
program (TPP) 
on changes in 
BZD and other 
A) New York (N=6,054): 
reside in New York; ≥19 
years; continuously 
enrolled in Medicaid for 
≥10 out of 12 months 
for 1988-1990 and 1995; 
≥1 inpatient or ≥2 
1) Probably problematic behavior: 
dispensed same BZD from ≥2 pharmacies 
(7 days) OR  
BZD use >2 times MRDD (time period not 
reported) 
Rate in 1988 to 1990 rates [% change] 
A) 7.1 to 2.4 [-4.7%] 
*Probably non-problematic 
BZD use (BZD use of ≤120 
days, no pharmacy hopping 
or high daily dose) was 
affected to a greater extent 
by TPP then problematic BZD 
use. 
*6 months post-TPP, 
anxiolytic use increased 
85.7% in New York, 
sedative-hypnotic use 
increased 35.0%. There 
were no changes in 
utilization for BZDs in New 
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psychoactive 
drug use 
compared to 
New Jersey (no 
TPP). 
outpatient diagnoses of 
a specified mood 
disorder in 1988.  
B) New Jersey 
(N=6,875): A) but reside 
in New Jersey. 
B) 4.0 to 3.4 [-0.6%] 
 
*The implementation of the 
TPP resulted in abrupt, large 
and sustained reductions in 
BZD use among chronically ill 
users in New York relative to 
identically defined users in 
New Jersey who were not 
exposed to TPP. 
Jersey. 
*Reduction in BZD use was 
sustained 7 years after TPP. 
 
Skurtveit42 
2011 
Norway 
(2005-2008) 
 
Determine 
prevalence of 
persistent/ 
problematic 
opioid use. 
A) Cohort (N=245,006):  
≥1 dispensings of a weak 
opioid (codeine, 
tramadol or 
dextropropoxyphene). 
Excluded if: received any 
opioid for palliative 
treatment of malignant 
disease. 
 
Strong opioids: 
buprenorphine, 
fentanyl, 
hydromorphone, 
ketobemidone, 
morphine, oxycodone, 
pentazocine and 
pethidine. 
1) Persistent user: dispensed ≥1 opioid 
(not further specified) each year from 
2005 to 2008; in 2008 dispensed >365 
DDD of opioids in 2008 (48 months) 
A) 0.3% (n=686) 
2) Milder probable problematic user 
indicator: dispensed ≥1 opioid (weak or 
strong) in each year from 2005 to 2008; in 
2008 dispensed >365 DDD of opioids and 
≥4 prescribers (48 months) 
A) 0.2% (n=421) 
3) Probable problematic user: dispensed 
≥1 opioid (weak or strong) in each year 
from 2005 to 2008; in 2008 dispensed 
>365 DDD of opioids; ≥4 prescribers and 
>100 DDD of BZDs (48 months) 
A) 0.08%  (n=191) 
4) Stricter probable problematic user 
indicator: dispensed ≥1 opioid (weak or 
strong) in each year from 2005 to 2008; in 
2008 dispensed >365 DDD of opioids; ≥4 
prescribers and >300 DDD of BZDs (48 
months) 
A) 0.06% (n=139) 
5) Strictest probable problematic user 
*9.5% of codeine users, 
21.0% of tramadol users, and 
22.3% of 
dextropropoxyphene users 
(in 2008) were dispensed a 
LA opioid as their first opioid 
in 2005.  
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indicator: dispensed ≥1 opioid (weak or 
strong) in each year from 2005 to 2008; in 
2008 dispensed >365 DDD of opioids; ≥7 
prescribers and >100 DDD of BZDs (48 
months) 
A) 0.05% (n=126) 
Soumerai43 
2003 
US 
(1987-1990) 
Determine if 
pharmacy 
hopping is 
associated with 
dose escalation 
in long term BZD 
users (≥2 years) 
and identify 
predictors of 
dose escalation. 
 
A) Entire cohort 
(N=2,440): ≥2 years of 
BZD use; enrolled in 
Medicaid for ≥10 out of 
12 months per year 
1987-1990. (B + C) 
B) Continuing BZD user 
(N=1,980) A) but ≥2 
years of BZD use 
between 1988-1990. 
C) Incident BZD user 
(N=460): A) but no BZD 
use before Dec 1987. 
1) Pharmacy hoppers: dispensed same 
BZD from ≥2 pharmacies (7 days) 
A) 7.4% (n=180) 
B) 7.0% (n=139) 
C) 8.9% (n=41) 
2) Users escalated to 'high' dosages: 20 
(elderly patients) or 40 (younger patients) 
diazepam milligram equivalents per day 
(24 months) 
A) 1.6% (n=40) 
B) 1.3% (n=26) 
C) 3.0% (n=14) 
 
*Predictors of dose 
escalation: 
B+C) regular use of SA, high 
potency BZD lorazepam; or 
young users (<45 years).  
B) Use of antidepressants 
and pharmacy hopping (OR 
5.2). 
*Long-term use of BZDs is 
not associated with notable 
dose escalation. 
 
Sullivan44 
2010 
US 
(2000-2005) 
Validate an 
indicator of 
opioid misuse 
and determine 
the 
demographic, 
clinical, and 
pharmacological 
risks associated 
with opioid 
misuse. 
 
A) Commercially 
insured (N=21,685): ≥18 
years; chronic opioid 
user, i.e. ≥90 days of 
opioid use in any 6 
month period between 
Jan 2001-Dec 2004; 
continuous enrolment 
12 months prior to and 
post index date (first 
opioid dispensing); 
identified in HealthCore 
dataset. Excluded if: ≥32 
day gap in opioid use; 
1) Opioid misuse score: based on excess 
days supplied short- and long-acting 
opioids, number of dispensing 
pharmacies and prescribers (6 months). 
Score 0-1: no misuse 
A) 70.0% (n=15,180) 
B) 76.0% (n=7,721) 
Score 2-4: possible misuse 
A) 24.0% (n=5,205) 
B) 20.0% (n=2,032) 
Score ≥5: probable misuse 
A) 6.0% (n=1,302) 
B) 3.0% (n=305) 
*For commercially insured 
cohort, risk of diagnosis of 
opioid abuse increased 41% 
for every 1 point increase in 
opioid misuse score.  
*For publically insured 
cohort, risk of diagnosis of 
opioid abuse increased 51% 
for every 1 point increase in 
opioid misuse score. 
*Factors that increase risk of 
opioid misuse: younger age, 
back pain, multiple pain 
complaints, substance abuse 
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cancer diagnosis within 
12 months of index date 
(pre- or post-); resident 
of nursing home or 
hospice user. 
B) Publically insured 
(N=10,159): A) but 
identified in Arkansas 
Medicaid. 
disorder, high daily dose of 
opioids (>120 mg MED/day) 
and shorting acting schedule 
II opioids. 
 
Thirion45 
2002 
France 
(Sep-Dec 
1999) 
Identify and 
profile deviant 
users dispensed 
buprenorphine 
(opioid). 
A) Cohort (N=2,078): ≥1 
buprenorphine 
dispensings. 
1) Deviant: ≥3 prescribers or dispensed 
>20 mg/day of buprenorphine (4 months) 
A) 18.1% (n=377) 
 
*Number of prescribers (4 
months) 
1 prescriber: 66% (n=1,371) 
2 prescribers: 22% (n=457) 
3-5 prescribers: 11% (n=229) 
≥6 prescribers: 1% (n=21) 
*Deviant group profile: 
younger, male and higher 
consumption of BZDs. 
*Mean (SD) prescriptions (4 
months) 
Deviant user: 10.1 (5.9) 
Victorri-
Vigneau46 
2006 
France 
(second half 
of years 
2001, 2002 
and 2003) 
Demonstrate 
impact of 
intervention 
program to 
reduce 
excessive doses 
of psychotropic 
drugs (medicine 
class not further 
specified). 
A) Intervention cohort 
(N=1,390) reside in Pays 
de Loire; dispensed >2 
times maximum 
recommended daily dose 
(MRDD) for ≥3 
consecutive months for 
one psychotropic drug. 
(Includes but is not 
limited to cohorts B and 
C.) 
B) No action cohort 
(N=422): A) and 
reimbursement code 
related to “serious 
problems of behavior 
and personality”. 
C) Action cohort 
Proportion of cohort pre-intervention to 
post-intervention 
1) >2 times MRDD (3 consecutive months) 
A) 100% (n=1,390) to 89.5% (n=1,244) 
B) Figures not reported (reduction of 
58.5% of patients meeting this criteria) 
C) Figures not reported (reduction of 66% 
of patients meeting this criteria) 
D) Figures not reported (reduction of 
46.2% of patients meeting this criteria) 
2) Excess consumption: average daily 
consumption exceeds MRDD specified in 
drug monograph (change from pre- to 
post-intervention)  (12 months) 
A) Not reported 
B) 2.5 to 2.1 [-15%] 
C) 2.6 to 1.9 [-27%]  
D) 2.3 to 2.1 [-9%] 
*Mean number of prescribers  
(12 months) [% change] 
B) Mean not reported [-4%] 
C) 2.67 to 2.28 [-15%] 
D) Mean not reported [2%] 
(direction of change not 
reported) 
*R ratio: number of patients 
receiving >2 MRDD of 
psychotropic medicine to 
number of patients receiving 
psychotropic medicine 
C) 100% (n=840) to 33.4% 
(n=281). 
*When considering all 
persons dispensed 
psychotropic medicine, the R 
ratio decreased by 14.1% 
*Health professionals 
involved with ‘action 
cohort’ filed 116 drug 
addiction reports. The 
prevalence of medicines 
mentioned in these 
reports: 
Zopiclone: 19% 
Zolpidem: 17% 
Oxazepam: 16% 
BZD (other): 13% 
Meprobamate: 11% 
Clorazepate: 9% 
Buprenorphine: 8% 
Bromazepam: 7% 
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(N=840): A); doctors and 
pharmacists of identified 
users received a letter to 
review their patients’ 
medical prescriptions. 
Excluded if: assigned to 
B); refusal to have data 
included in study; death, 
or moved residence. 
D) Comparison cohort (N 
not reported): A) but 
reside in Vendee. 
 
 
over the study period. 
 
 
Victorri-
Vigneau47 
2011 
France 
(Jul-Dec 
2005) 
Characterize AD 
over-
consumption. 
 
A) Tianeptine 
(N=7,264): ≥2 tianeptine 
dispensings. [MRDD = 
37.5 mg] 
B) Milnacipran 
(N=1,918): ≥2 
milnacipran dispensings. 
[MRDD = 100 mg] 
 
1) Overconsumer: dispensed more 
medicine than medically required (6 
months) 
A) Dispensed 1.7 times the MRDD: 0.4% 
(n=29) 
B) Dispensed 2 times the MRDD: 2.4% 
(n=46)  
2) Pharmacy shoppers: ≥4 dispensing 
pharmacies (6 months)  
•In tianeptine overconsumers (n=29): 
20.7% (n=6) 
•Other tianeptine users (n=7,235): 1.0% 
(n=72) 
•Milnacipran overconsumers (n=46): 4.3% 
(n=2) 
•Other milnacipran users (n=1,872): 1.4% 
(n=26) 
3) % R ratio>1: observed number of 
dispensings delivered to the user is 
greater than the amount actually 
required (6 months) 
*Median (range) prescribing 
physicians (6 months) 
A) 1 (1-6) 
B) 1 (1-5) 
*Median (range) dispensing 
pharmacies (6 months) 
A) 1 (1-13) 
B) 1 (1-6) 
*Median (range) dispensings 
(6 months) 
A) 5 (2-40) 
B) 4 (2-17) 
*Consumption factor >1: 
estimate of average daily 
consumption of a 
psychotropic drug divided by 
the MRDD (6 months) 
A) 17.2% (n=125) 
B) 32.3% (n=620) 
*The consumption factor 
reached higher values for 
tianeptine (up to 11 times 
higher) but occurred less 
frequently compared to 
milnacipran.  
*Pharmacy shopping 
increased risk of 
overconsumption for 
tianeptine (OR 10.78). 
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•Tianeptine overconsumers: 89.7% (n=26) 
•Other tianeptine user: 27.9% (n=2,015) 
•Milnacipran overconsumers: 93.5% 
(n=43) 
•Other milnacipran users: 29.9% (n=560) 
Victorri-
Vigneau48 
2013 
France 
(Feb-Jul 
2010) 
Identify and 
characterize 
zolpidem and 
zopiclone (Z-
drugs) users. 
 
A) Zopiclone 
(N=21,860): ≥1 
zopiclone dispensings; 
number of dispensings 
are equal to or higher 
than medically required 
rate (3.75 mg).  
B) Zolpidem (N=25,168): 
≥1 zolpidem 
dispensings; number of 
dispensings are equal to 
or higher than medically 
required rate (5 mg). 
1) Problematic user: latent class analysis 
based on: prescribing physician type, 
doctor shopping, pharmacy shopping, 
excess use, agreement with practice 
guidelines and associated psychiatric 
disorders (6 months) 
A) 0% (n=0) 
B) 1.0% (n=252) 
2) Doctor shopper: ≥4 prescribers (6 
months) 
A) 1.1% (n=241) 
•In problematic zopiclone users: 0% (n=0) 
B) 1.0% (n=252) 
•In problematic zolpidem users: 47.2% 
(n=119) 
3) Pharmacy shopper: ≥4 dispensing 
pharmacies (6 months) 
A) 1.7% (n=372) 
•In problematic zopiclone users: 0% (n=0) 
B) 2.1% (n=529) 
•In problematic zolpidem users: 84.1% 
(n=212) 
4) Excess use: medication possession ratio 
(MPR) >1: number of medicine supply 
days excluding last refill divided by the 
number of days between the first and last 
dispensing (6 months) 
A) 32.8% (n=7,171) 
*Problematic users mean 
(SD) daily dose (mg/day) (6 
months) 
A) 0 (0) 
B) 20.9 (2.4) 
*Zolpidem ‘problematic’ 
users were younger, average 
daily dose was higher and 
the number of dispensings is 
2-fold higher.  
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•In problematic zopiclone users: 0% (n=0) 
B) 31.2% (n=7,853) 
•In problematic zolpidem users: 75.0% 
(n=189) 
Wainstein49 
2011 
France 
(Jan-Jun 
2008) 
Characterize 
consumption 
behavior related 
to three 
psychotropic 
drugs (BZD, Z-
drugs and AD).  
 
A) Bromazepam 
(N=40,644): ≥18 years; 
≥2 bromazepam 
dispensings.  
[MRDD = 18 mg]. 
B) Zolpidem (N=36,264) 
≥18 years; ≥2 zolpidem 
dispensings.  
[MRDD = 10 mg]. 
C) Paroxetine 
(N=31,235): ≥18 years; 
≥2 paroxetine 
dispensings.  
[MRDD = 40 mg]. 
 
Excluded if: 2 
dispensings received on 
the same day. 
 
1) Problematic user: latent class analysis 
based on excessive medicine use, 
prescribing physician specialty, ‘doctor 
shopping’ behavior, ‘pharmacy shopping’ 
behavior, prescription in agreement with 
practice guidelines (6 months) 
A) 1.0% (n=407) 
B) 1.0% (n=363) 
C) 0% (n=0) 
2) Pharmacy shoppers: ≥4 dispensing 
pharmacies (6 months) 
A) 1.2%  (n=488) 
•In problematic bromazepam users: 
93.1% (n=379) 
B) Not reported 
• In problematic zolpidem users: 65.0% 
(inferred from graph) (n=236) 
C) Not reported 
• In problematic paroxetine users: 0%  
3) Doctor shoppers: ≥4 prescribers 
doctors (6 months)  
A) 0.4% (n=163) 
• In problematic bromazepam users: 
41.0% (n=167) 
B) Not reported 
• In problematic zolpidem users: 32% 
(inferred from graph) (n=117) 
C) Not reported 
• In problematic paroxetine users: 0% 
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4) Estimate of average daily consumption 
of a psychotropic medicine greater than 
MRDD (6 months) 
A) 1.1% (n=448) 
• In problematic bromazepam users: 
56.0% (n=228) 
B) 17.8% (n=6,455) 
•In problematic zolpidem users: 89.0% 
(inferred from graph) (n=324) 
C) 0.3% (n=94) 
•In problematic paroxetine users: 0% 
(n=0) 
White50  
2009 
US  
(2005-2006) 
 
Assess feasibility 
of using medical 
and prescription 
drug claims to 
develop models 
that identify 
prescription 
opioid abuse or 
misuse. 
 
Model A cohort details. 
A) Cohort (N=116,382): 
aged 12-64, ≥1 opioid 
claim and ≥1 medical 
claim. (B + C) 
B) Abusers (N=875): A) 
ICD-9-CM code of opioid 
dependence or 
poisoning  
C) All other individuals 
(N=115,507): A) not B) 
 
Model B cohort details 
D) Cohort (subset of A) 
(N=8,592): A) claims 
occurred Sep-Dec 2006.  
(E + F) 
E) Abusers (N=303): B) 
between Sep-Dec 2006. 
F) All other individuals 
(N=8,289): C) not E). 
1) Number of prescribers: ≥2 prescribers 
(3 months) 
A) not analyzed: D) 26.1% (n=2,242) 
B) not analyzed: E) 40.9% (n=124) 
C) not analyzed: F) 25.6% (n=2,118) 
2) Pharmacy shopper: ≥2 dispensing 
pharmacies (3 months) 
A) 7.9% (n=9,213): D) 19.9% (n=1,708) 
B) 39.4% (n=345): E) 38.0% (n=115) 
C) 7.7% (n=8,868): F) 19.2% (n=1,593) 
3) ≥4 opioid prescriptions (3 months) 
A) 10.1% (n=11,740): D) not analyzed 
B) 60.1% (n=526): E) not analyzed 
C) 9.7% (n=11,214): F) not analyzed 
4) ≥1 early refills of opioid prescriptions: 
two consecutive opioid prescriptions 
where days of supply of first prescription 
was >10% higher than the number of days 
between prescriptions (3 months) 
A) 4.0% (n=4,615): D) 16.5% (n=1,414) 
B) 36.0% (n=315): E) 40.9% (n=124) 
*Factors associated with ICD 
code of opioid abuse, 
dependence or poisoning 
(not related to an outcome 
measure defining misuse): 
male (OR 2.19), ≥3 
dispensing pharmacies (OR 
1.96), ≥1 early refills of 
opioid prescriptions (OR 
6.52), ≥2 consecutive months 
of dose escalation (OR 1.59), 
≥12 opioid prescriptions (OR 
2.12), ≥1 non-opioid 
substance abuse diagnosis 
(OR 5.83).  
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C) 3.7% (n=4,300): F) 15.6% (n=1,290) 
5) Dose escalation: 50% increase in the 
mean milligrams of morphine per month 
for 2 consecutive months (3 months) 
A) 0.4% (n=509): D) not analyzed 
B) 4.7% (n=41): E) not analyzed 
C) 0.4% (n=468): F) not analyzed 
Wilsey51 
2010 
US 
(2007) 
 
Determine 
prevalence and 
predictors of 
multiple 
provider 
episodes (MPEs) 
for different 
controlled 
substances. 
 
A) Cohort (N not 
reported): prescription 
for schedule II-IV 
controlled substances. 
Excluded if: missing or 
incomplete user or 
provider identification; 
implausible 
prescriptions; use of 
medications not 
suggestive of standard 
delivery systems 
employed by most 
users. 
Prescription level data 
(N=27,773,347) 
1) Prescriptions obtained by multiple 
provider episodes (MPEs): ≥2 prescribers 
and ≥2 dispensing pharmacies (30 days) 
A) 8.4% (n prescriptions=2,332,962) 
2) Proportion of prescription obtained by 
MPEs by drug class: 
Opioids: 12.8% 
BZDs: 4.2% 
Stimulants: 1.4% 
Anorectics: 0.9% 
 
*Risk of simultaneous MPEs 
for different controlled 
substances: 
i) Opioids and: 
BZD: OR 15.54 
Stimulants/anorectics: OR 
10.56 
BZD and 
stimulants/anorectics: OR 
21.40 
ii) BZD and: 
Opioids: OR 13.04 
Stimulants/anorectics: OR 
20.60 
Stimulants/anorectics and 
opioids: OR 3.64 
iii) Stimulant and: 
BZD: OR 19.62 
Opioids: OR 9.23 
BZD and opioids: OR 26.83 
iv) Anorectic and: 
BZD: OR 9.95 
Opioids: OR 11.06 
BZD and opioids: OR 27.16 
*For opioids: 
hydromorphone and 
controlled release 
oxycodone were most 
associated with MPEs. 
*Younger age predictor of 
MPEs associated with 
opioid and BZDs. 
*Older age associated with 
MPE use to obtain 
stimulants and anorectics.  
*Males were more likely to 
use MPE for BZD; less likely 
for stimulants; no gender 
relationship between 
anorectics or opioids.  
*Strongest predictor was 
simultaneously receiving 
prescriptions for different 
controlled substances and 
concurrent use of multiple 
prescribers to obtain other 
controlled substances. 
Wilsey52 
2011 
Determine if 
persons 
A) Cohort 
(N=12,870,831)  
1) Multiple prescribers: 2-5 prescribers 
(12 months) 
*Single prescriber (12 
months) 
*Persons accessing 2-5 
prescribers are different 
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US 
(1999-2007) 
accessing 2-5 
prescribers were 
distinguishable 
from persons 
accessing 1 
prescriber in 
demographic 
characteristics 
or opioid 
utilization 
(opioid). 
 
Prescribed same 
schedule II or III opioid 
in 12 months. Excluded 
if: missing/incomplete 
prescription, pharmacy 
or prescriber 
information; implausible 
prescription; use of 
opioids not suggestive 
of chronic pain. 
A) 22.1% (n=2,849,464) 
2) Frequency of use of multiple prescribers 
per drug (12 months) 
Hydrocodone (schedule III): 68.3% 
Codeine (schedule III): 9.8% 
Oxycodone IR (schedule II): 7.8% 
Oxycodone ER (schedule II): 3.0% 
Fentanyl (transcutaneous) (schedule II): 
4.0% 
Morphine ER (schedule II): 3.2% 
Methadone (schedule II): 1.5% 
Hydromorphone (schedule II): 1.5% 
Morphine IR (schedule II): 0.6% 
Fentanyl (oral transbuccal): 0.1% 
Meperidine (schedule II): 0.1% 
Levorphanol (schedule II): 0.02% 
A) 77.9% (n=10,021,367) 
*Persons accessing 2-5 
prescribers were more likely 
to use LA opioids than 
hydrocodone (ranging from 
7.8% [fentanyl patch] to 
38.8% [methadone]) and less 
likely to use SA opioids. 
*Likelihood of MPEs 
increased with age. 
*Persons with multiple 
prescribers were more likely 
to: be female; reside in a 
small geographic area.  
 
 
from those using one 
prescriber, but differences 
do not suggest abuse. 
 
a See Electronic Supplementary Material 6 for reference list. 
bPeriod of observation covers the entire year, unless otherwise stated. 
cReported aim(s) and cohort(s) may differ from original article as we only report aspects of paper related to prescription drug misuse. 
dWe renamed/redefined some measures from the original manuscript for clarity and due to space constraints. If either a rate or the number of people 
identified by a measure was not reported, where possible we calculated it. All reported rates were derived from drug user or misuse cohorts unless 
otherwise stated. 
 
ACRONYMS: 
AD(s): antidepressant(s) 
AP: antiparkinson 
BMT: buprenorphine maintenance therapy 
BZD(s): benzodiazepine(s) 
DDD: defined daily dose 
DSI: doctor shopping indicator 
DSQ: doctor shopping quantity 
DZE: diazepam milligram equivalent 
ED: emergency department 
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ER: extended release 
GP(s): general practitioner(s) 
HDB: high dosage buprenorphine 
ICD: International Classification of Diseases 
IR: immediate release 
LA: long acting 
MPE(s): multiple provider/prescriber episode(s) 
MRDD: maximum recommended daily dose 
OMT: opioid maintenance therapy 
OR: odds ratio 
PMP: prescription monitoring program 
PTSD: Post-Traumatic Stress Disorder 
SA: short acting
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Electronic Supplementary Material 8 The Reported Extent of Prescription Drug Misuse Based on Indicators 
with a Defined Threshold 
Electronic Supplementary Material 8.1 Proportion of Cohort Identified as ‘Misusers’ Based on Indicators with 
a Defined Threshold 
A. Stand-alone measures of misuse (drug users only) 
Stand-alone measure details 
(A single behavior of misuse measured in drug users: persons 
dispensed the drug of interest) 
Time 
period 
(days)a 
Drug user 
cohortb 
Referencec 
Number of prescribers 
≥2 prescribers 90 26.1 
50 
2-5 prescribers  365 22.1 
52 
≥3 prescribers  365 NM 
16 
≥4 prescribers  180 0.9 
2 
≥4 prescribers NR 0.5 
3 
≥4 prescribers 180 3.6 
33 
≥4 prescribers 180 1.1 
48 
≥4 prescribers 180 0.4 
49 
Number of dispensing pharmacies 
≥2 dispensing pharmacies  7 1.9 
32 
≥2 dispensing pharmacies  7 3.9 
38 
≥2 dispensing pharmacies  7 8.9 
43 
≥2 dispensing pharmacies 90 19.9 
50 
≥4 dispensing pharmacies  180 1.3 
2 
≥4 dispensing pharmacies 180 1.3 
33 
≥4 dispensing pharmacies 180 1.4 
47 
≥4 dispensing pharmacies 180 2.1 
48 
≥4 dispensing pharmacies 180 1.2 
49 
Volume of drug dispensed 
≥1 benzodiazepine dispensings per year for 4 consecutive years 1440 2.2 
20 
≥4 dispensings 90 10.1 
50  
>15 defined daily doses of carisoprodol 365 32.2 
3 
≥100 defined daily doses of opioids 365 13.6 
3 
>365 defined daily doses of codeine 365 5.8 
14 
>1000 defined daily doses of carisoprodol  365 0.2 
4 
Daily dose ≥100 morphine milligram equivalent 365 7.8 
23 
Daily consumption of drug greater than maximum recommended 
daily dose  
180 17.8 49 
>2 times maximum recommended dose Various 9.2 
38 
≥2 times maximum daily dose 180 2.4 
47 
Number of dispensings greater than medically required 180 29.9 
47 
Overlapping prescriptions or early refills 
≥1 early refills: two consecutive prescriptions for same drug with 
number of days between prescriptions being >10% lower than 
number of days’ supply in first prescription  
365 6.9 22 
1 early refill: prescription filled >7 days before the end of previous 
prescription 
365 33.8 40 
≥1 early refills: two consecutive opioid prescriptions where days 90 16.5 
50 
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of supply was >10% higher than number of days between 
prescriptions 
≥1 early refills: prescription opioid refill that occurred with >25% 
of the days’ supply remaining on the previous prescription for the 
same active ingredient  
365 4.1 37 
≥4 days of overlapping prescriptions 540 11.1 
5 
≥7 days of overlapping prescriptions 365 2.1 
23 
Use of specific prescribed drug 
Long acting or extended release opioids prescribed for acute pain 
conditions  
365 0.1 23 
Use of ≥4 different benzodiazepines Various 1.9 
38 
Receipt of long half-life benzodiazepines (persons aged ≥65 years) NR 51.3 
38 
Duration of treatment 
Median duration of opioid use ≥2 months  365 63.2 
40 
>120 days of benzodiazepine treatment Various 41.9 
38 
Dose escalation 
Users escalating to ‘high’ dosages: 20 (elderly patients) or 40 
(younger patients) diazepam milligram equivalents per day 
NR 3.0 43 
50% increase in mean milligrams of morphine per month for 2 
consecutive months 
90 0.4 50 
a All time periods have been converted to days, i.e. 30 days = 1 month; 90 days = 3 months; 180 days = 6 
months; 365 days = 12 months etc. NR = not recorded in original manuscript. 
b If study reported rates for >1 drug user cohort or drug, we record the highest reported rate alone. 
c See Electronic Supplementary Material 6 for reference list. 
NM = no meaningful result was obtained. 
NR = not recorded in original manuscript. 
 
B. Composite measures: a single measure of misuse reported in a misuse cohort (where 
possible, we also record the extent of misuse in a drug user cohort) 
Composite measure of misuse details  
 (A single behavior of misuse measured in a defined 
misuse cohort) 
Misuse cohort definition 
Time 
period 
(days)a 
Drug user 
cohortb 
Misuse 
cohortb 
Referencec 
Number of prescribers 
≥2 prescribers 
Misuse cohort definition: ICD-9 code of opioid abuse, 
dependence or poisoning 
90 26.1 40.9 50 
≥3 prescribers 
≥1 days of overlapping prescriptions 
540 (0.7) 5.4 5 
≥4 prescribers  
2 defined daily doses (DDD)/day of carisoprodol; 
dispensed <100 DDD of opioids, and dispensed <100 DDD 
of benzodiazepines in 365 days 
NR 0.6 4.5 3 
≥4 prescribers  
Drug-related death 
180 3.6 25.2 33 
≥4 prescribers  
≥4 dispensing pharmacies 
180 (0.7) 55.6 33 
≥4 prescribers 
Highest 1% zolpidem users determined by latent class 
analysis 
180 (0.5) 47.2 48 
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≥4 prescribers 
Highest 1% bromazepam users determined by latent 
class analysis 
180 (0.4) 41.0 49 
 ≥5 prescribers 
Pharmaceutical overdose death 
365 N/A 21.4 18 
Number of dispensing pharmacies 
≥2 dispensing pharmacies 
Misuse cohort definition: ≥1 days of overlapping 
prescriptions 
540 (2.8) 21.3 5 
≥2 dispensing pharmacies  
ICD-9 code of opioid abuse, dependence or poisoning 
90 19.9 39.4 50 
≥3 dispensing pharmacies 
≥1 days of overlapping prescriptions 
540 (0.2) 1.3 5 
≥4 dispensing pharmacies 
Drug-related death 
180 1.3 17.5 33 
≥4 dispensing pharmacies 
≥4 prescribers 
180 (0.7) 20.2 33 
≥4 dispensing pharmacies 
Dispensed 1.7 or 2 times more drug than medically 
required 
180 1.4 20.7 47 
≥4 dispensing pharmacies 
Highest 1% zolpidem users determined by latent class 
analysis 
180 (0.8) 84.1 48 
≥4 dispensing pharmacies 
Highest 1% bromazepam users determined by latent 
class analysis 
180 (0.9) 93.1 49 
Volume of drug dispensed 
>2 times maximum recommended daily dose (post-
intervention) 
Misuse cohort definition: Pre-intervention dispensed >2 
times maximum recommended daily dose 
90 N/A 89.5 46 
≥4 prescriptions 
ICD-9 code of opioid abuse, dependence or poisoning 
90 10.1 60.1 50 
>15 defined daily dose (DDD) of carisoprodol 
>365 DDD of codeine 
365 (1.7) 30.2 14 
≥16 mg per day of high dosage buprenorphine 
≥2 overlapping prescriptions and ≥2 prescribers 
480 (3.4) 8.5 34 
>100 defined daily dose (DDD) of benzodiazepines 
Dispensed >365 DDD of codeine 
365 (2.9) 50.5 14 
>730 defined daily dose (DDD) of codeine 
Dispensed >365 DDD of codeine 
365 (1.1) 19.0 14 
Medication possession ratio >1: number of drug supply 
days excluding last refill divided by the number of days 
between the first and last dispensing. 
Number of dispensings greater than medically required 
180 N/A 32.8 48 
Number of dispensings greater than medically required 
Dispensed 1.7 or 2 times more drug than medically 
required 
180 29.9 93.5 47 
Amount of drug dispensed greater than medically 
required 
Highest 1% zolpidem users determined by latent class 
180 (0.8) 75.0 48 
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analysis 
Daily consumption of drug greater than medically 
required 
Highest 1% zolpidem users determined by latent class 
analysis 
180 (0.9) 89.0 49 
Overlapping prescriptions or early refills 
≥1 early refills: two consecutive opioid prescriptions 
where days of supply was >10% higher than number of 
days between prescriptions 
Misuse cohort definition: ICD-9 code of opioid 
dependence or poisoning 
90 16.5 40.9 50 
≥1 early refills: any prescription opioid refill that 
occurred with >25% of the days’ supply remaining on the 
previous prescription for the same active ingredient  
ICD-9 code of opioid dependence or poisoning 
365 4.1 38.4 37 
Dose escalation 
50% increase in the mean milligrams of morphine in 2 
consecutive months  
Misuse cohort definition: ICD-9 code of opioid 
dependence or poisoning 
90 0.4 4.7 50 
a All time periods have been converted to days, i.e. 30 days = 1 month; 90 days = 3 months; 180 days = 6 
months; 365 days = 12 months etc. N/A = not applicable as study investigated measure in misuse cohort 
alone 
b Where studies report multiple results across drugs or user cohorts we record the highest reported rate. 
We calculated all bracketed and italicized values. Values were not reported in original manuscript. 
c See Electronic Supplementary Material 6 for reference list. 
 
 
C. Composite measures: measure of misuse with two or more behaviors or characteristics reported in 
drug user and/or misuse cohort(s) 
Composite measure details 
 (≥2 behaviors/characteristics of misuse measured in 
drug user and/or misuse cohorts) 
Misuse cohort definition (where applicable) 
Time 
period 
(days)a 
Drug user 
cohortb 
Misuse 
cohortb 
Referencec 
Composite measures of misuse including number of prescribers and/or number of dispensing pharmacies 
≥2 prescribers and ≥1 days overlapping prescriptions 540 13.9  
5 
≥2 prescribers and ≥1 days overlapping prescriptions 480 39.5  
34 
≥2 dispensing pharmacies in 7 days OR benzodiazepine 
treatment duration >120 days OR dispensed >2 times 
maximum recommended daily dose 
Various 42.8  32 
≥2 prescribers, ≥3 dispensing pharmacies and ≥1 days 
overlapping prescriptions  
540 NR  6 
≥2 prescribers, ≥3 dispensing pharmacies and ≥1 days 
overlapping prescriptions 
365 0.9  8 
≥2 prescribers, ≥3 dispensing pharmacies and ≥1 days 
overlapping prescriptions 
540 0.7  9 
≥2 prescribers, ≥3 dispensing pharmacies and ≥1 days 
overlapping prescriptions 
540 0.3  7 
≥2 dispensing pharmacies within 7 days OR dispensed >2 
times maximum recommended daily dose 
Various 3.4  41 
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≥3 dispensing pharmacies and ≥1 overlapping 
prescriptions 
540 0.2  5 
≥3 prescribers and ≥3 dispensing pharmacies 365 1.6  
22 
≥3 prescribers OR dispensed >20 mg/day of 
buprenorphine 
120 18.1  45 
≥4 prescribers and ≥4 dispensing pharmacies 365 0.5  
22 
≥4 prescribers, ≥1 opioid dispensings for 4 consecutive 
years and in final year dispensed >365 defined daily doses 
of opioids 
1460 0.2  42 
≥4 prescribers, ≥1 opioid dispensings for 4 consecutive 
years, in final year dispensed >365 defined daily doses 
(DDD) of opioids and >100 DDDs of benzodiazepines 
1460 0.08  42 
≥4 prescribers, ≥1 opioid dispensings for 4 consecutive 
years, in final year dispensed >365 defined daily doses 
(DDD) of opioids and >300 DDD of benzodiazepines 
1460 0.06  42 
≥5 prescribers and ≥5 dispensing pharmacies 365 0.2  
22 
≥5 shopping episodes: ≥2 prescribers, ≥3 dispensing 
pharmacies and ≥1 days overlapping prescriptions (1 
shopping episode) 
365 0.07  8 
≥5 shopping episodes: ≥2 prescribers, ≥3 dispensing 
pharmacies and ≥1 days overlapping prescriptions (1 
shopping episode) 
540 0.1  9 
≥6 shopping episodes: ≥2 prescribers, ≥3 dispensing 
pharmacies and ≥1 days overlapping prescriptions (1 
shopping episode) 
Misuse cohort definition: ≥2 prescribers, ≥3 dispensing 
pharmacies and ≥1 days overlapping prescriptions 
540 (0.03) 9.5 7 
≥7 prescribers, ≥1 opioid dispensings for 4 consecutive 
years, in final year dispensed >365 defined daily doses 
(DDD) of opioids and >100 DDD of benzodiazepines 
1460 0.05  42 
Opioid misuse score: possible misuse score (score 2-3): 
based on number of dispensing pharmacies, prescribers, 
and excess days supplied short- and long-acting opioids 
180 14.5  25 
Opioid misuse score: possible or probable misuse score 
(score 2-4). Score based on number of dispensing 
pharmacies, prescribers, and excess days supplied short- 
and long-acting opioids 
180 24.0  44 
Opioid misuse score: probable misuse score (score ≥4) 
Score based on number of dispensing pharmacies, 
prescribers, and excess days supplied short- and long-
acting opioids 
180 2.2  25 
Opioid misuse score: probable misuse score (score ≥5) 
Score based on number of dispensing pharmacies, 
prescribers, and excess days supplied short- and long-
acting opioids 
180 6.0  44 
≥2 letters sent out to physician informing them of 
patient’s problematic use of prescribed drug. Based on 
alerts of number of prescribers or dispensing pharmacies 
and/or amount of drug prescribed. 
Physician previously sent a letter describing patient’s 
problematic use of prescription drug(s) 
180 N/A 29.8 21 
 75 
 
 
Composite measures of misuse including volume of drug dispensed: none of the listed measures include 
number of prescribers or dispensing pharmacies. 
≥1 opioid dispensings for 4 consecutive years; and in final 
year dispensed >365 defined daily doses of opioids 
1460 0.3  42 
2 defined daily doses (DDD) per day of carisoprodol, <100 
DDD of benzodiazepines and <100 DDD of opioids 
365 1.0  3 
≥100 defined daily doses (DDD) of benzodiazepines and 
<100 DDD of opioids 
365 7.8  3 
≥2 dispensings of carisoprodol and dispensed: >15 
defined daily doses (DDD) of carisoprodol, >2 times 
recommended maximum daily dose for a period, <100 
DDD of opioids and <100 DDD of benzodiazepines  
365 1.0  4 
Dispensed ≥100 defined daily doses (DDD) of 
benzodiazepines and/or ≥15 DDD of carisoprodol 
365 50.1  1 
Dispensed ≥100 defined daily doses (DDD) of 
benzodiazepines OR ≥15 DDD of carisoprodol 
365 41.9  1 
Dispensed ≥100 defined daily doses (DDD) of 
benzodiazepines and ≥15 DDD of carisoprodol 
365 8.2  1 
Dispensed >2 times maximum recommended daily dose 
OR benzodiazepine treatment duration >120 days 
Various 40.2  32 
Composite measures of misuse including early refills or overlapping prescriptions: none of the measures 
listed include number of prescribers, dispensing pharmacies or volume of drug dispensed 
Opioid and BZD prescription with ≥7 days overlap 365 1.0  
23 
Concurrent use of 2 long acting benzodiazepines Various 1.1  
38 
Concurrent use of 2 short acting benzodiazepines Various 4.5  
38 
≥2 types of concurrent opioid use with >7 days overlap 30 19.8  
40 
≥2 types of concurrent sedative hypnotic use  30 40.7  
40 
a All time periods have been converted to days, i.e. 30 days = 1 month; 90 days = 3 months; 180 days = 6 
months; 365 days = 12 months etc. N/A = not applicable as study investigated measure in misuse cohort 
alone. NR = not recorded in original manuscript. 
b Where studies report multiple results across drugs or user cohorts we record the highest reported rate. 
We calculated all bracketed and italicized values. Values were not reported in original manuscript. 
c See Electronic Supplementary Material 6 for reference list. 
 
Electronic Supplementary Material 8.2. Proportion of misusers determined through empirical analysis. 
Empirical analysis details (empirically derived thresholds of misuse 
where relevant) 
Time 
period 
(days)a 
Drug user 
cohortb 
Referencec 
Excessive use based on Peaks Over Threshold model 180 7.2 
2 
Highest 1% of carisoprodol users based on Lorenz curve (dispensed 
≥480 defined daily doses) 
365 1.1 4 
Highest 10% of codeine users (≥120 defined daily doses) 365 10.7 
1 
Highest quintile (20%) of opioid users 365 22.7 
40 
Cluster analysis based on number of: prescribers; dispensing 
pharmacies; dispensing episodes and sum of DDD dispensed 
270 1.1 12 
Cluster analysis based on number of: prescribers; dispensing 
pharmacies; dispensing episodes and sum of DDD dispensed 
270 1.1 13 
Cluster analysis based on number of: prescribers; dispensing 
pharmacies; dispensing episodes and sum of DDD dispensed 
270 6.0 29 
Cluster analysis based on number of: prescribers; dispensing 270 9.1 
30 
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pharmacies; dispensing episodes and sum of DDD dispensed 
Latent class analysis based on gender; age and method of payment 300 0.7 
26 
Highest 1% of drug users based on latent class analysis including 
consumption factor; prescriber specialty; number of prescribers; 
number of dispensing pharmacies; consistent with practice guidelines 
180 1.0 49 
Highest 1% of drug users based on latent class analysis including 
prescriber specialty; number of prescribers; number of dispensing 
pharmacies; excess use; consistent with practice guidelines; 
associated psychiatric disorders 
180 1.0 48 
a All time periods have been converted to days, i.e. 180 days = 6 months; 365 days = 12 months etc. 
b Where studies report multiple results across drugs or user cohorts we record the highest reported rate. 
c See Electronic Supplementary Material 6 for reference list.
 77 
 
 
Electronic Supplementary Material 9 The Proportion of Prescription Drugs Dispensed to a Misuse 
Cohort: Determined by a Measure of Misuse with a Defined Threshold 
A. Stand-alone and composite measures of misuse reporting the proportion of drugs dispensed 
to misuser cohorts 
Drug class of interest (unit of measurement) 
(Misuse cohort definition) 
Time 
period 
(days)a 
Proportion of 
drug class 
dispensed to a 
misuse cohort 
Referenceb 
Anorectics 
Misuser cohort definition: ≥2 prescribers and ≥2 dispensing 
pharmacies 
30 0.9 51 
Benzodiazepines 
≥2 prescribers and ≥2 dispensing pharmacies 
7 1.2 10 
Benzodiazepines  
≥2 prescribers and ≥2 dispensing pharmacies 
30 4.2 51 
Opioids 
≥2 prescribers and ≥2 dispensing pharmacies 
7 3.2 10 
Opioids 
≥2 prescribers and ≥2 dispensing pharmacies 
30 9.6 15 
Opioids 
≥2 prescribers and ≥2 dispensing pharmacies 
30 12.8 51 
Opioids 
≥3 prescribers and ≥3 dispensing pharmacies 
365 7.7 22 
Opioids  
≥4 prescribers and ≥4 dispensing pharmacies  
365 3.1 22 
Opioids  
≥5 prescribers and ≥5 dispensing pharmacies 
365 1.5 22 
Stimulants 
≥2 prescribers and ≥2 dispensing pharmacies 
30 1.4 51 
Prescription drug of interest (unit of measurement) 
(Misuse cohort definition) 
Time 
period 
(days)a 
Proportion of 
drug dispensed to 
a misuse cohortc 
Referenceb 
Buprenorphine 
Misuse cohort definition: Doctor shopping quantity: amount 
of excess drug obtained by misusers by overlapping 
prescriptions from ≥2 prescribers 
485 18.7 34 
Hydrocodone 
≥2 prescribers 
365 68.3 52 
Hydromorphone 
≥2 prescribers and ≥2 dispensing pharmacies 
30 15.2 15 
a All time periods have been converted to days, i.e. 30 days = 1 month; 365 days = 12 months etc. 
b See Electronic Supplementary Material 6 for reference list. 
c Per drug class, we report the result of the drug with the highest DSI. 
 
B. Composite measures of misuse reporting the volume of drugs dispensed to misuse cohorts: specific 
measures of doctor shopping quantity (DSQ) and doctor shopping indicator (DSI) 
Drug class or drug of interest 
Time 
period 
(days)a 
Measure of 
misuse: 
DSQb 
Measure of 
misuse: 
DSI (%)b 
Referencec 
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Doctor shopping quantity (DSQ): amount of excess drug obtained by misusers by overlapping 
prescriptions from ≥2 prescribers 
Doctor shopping indicator (DSI) (%): amount of drug calculated by the DSQ, expressed as the 
proportion of total drug dispensed (i.e. DSQ/total drug volume dispensed). DSI >1% is a signal for 
drug abuse. 
Drug class 
Benzodiazepines NR 
d 1.9 31 
Benzodiazepines 365 361,428 DDD NR 
36 
Opioids (OMT) 
365 
55.3 DDD/1000 
population  
6.2 27 
Antidepressants 
Mianserin 365 15,344 DDD 1.0 
39 
Benzodiazepine 
Flunitrazepam 365 
d 27.0 30 
Flunitrazepam 365 108,727 DDD 42.8 
36 
Flunitrazepam 365 436,647 DDD 30.2 
39 
Opioids 
Buprenorphine 365 1151 grams 21.7 
35 
Buprenorphine (opioid maintenance therapy) 
365 
50.3 DDD/1000 
population 
8.0 27 
Buprenorphine (opioid maintenance therapy) NR 
d 12.5 31 
Z-drugs 
Zolpidem 365 
d 2.5 30 
Zolpidem 365 499,010 DDD 2.2 
39 
a All time periods have been converted to days, i.e. 365 days = 12 months etc. NR = not recorded in 
original manuscript. 
b Per drug class, we report the result of the drug with the highest DSI. 
c See Electronic Supplementary Material 6 for reference list. 
d DSQ not investigated in study 
 
C. Proportion of drug dispensed to empirically defined misuse cohort 
Empirical analysis details 
Time 
period 
(days)a 
Proportion of 
drug of interest 
dispensed to 
misuse cohortb 
Referencec 
Highest 1% of benzodiazepine drug users based on 
Lorenz curve 
365 16.5 16 
Highest 1% of carisoprodol users 365 18.7 
4 
Highest 1% of biperiden drug users based on Lorenz 
curve 
365 6.2 16 
a All time periods have been converted to days, i.e. 365 days = 12 months etc. 
b Where studies report multiple results relating to one drug class we report the drug with the highest 
rate. 
c See Electronic Supplementary Material 6 for reference list. 
